

# STIC Search Report

## Biotech-Chem Library

STIC Database Tracking Number: 164479

TO: Rei-Tsang Shiao  
Location: 5a10 / 5c18  
Art Unit: 1626  
Thursday, September 22, 2005

Case Serial Number: 10/693327

From: Noble Jarrell  
Location: Biotech-Chem Library  
Rem 1B71  
Phone: 272-2556

Noble.jarrell@uspto.gov

### Search Notes

=> d his full

(FILE 'HOME' ENTERED AT 08:52:27 ON 22 SEP 2005)

FILE 'HCAPLUS' ENTERED AT 08:52:42 ON 22 SEP 2005

L1 1 SEA ABB=ON PLU=ON US2004162278/PN OR (US2003-693327# OR  
GB2002-24919# OR US2002-428632#)/AP,PRN

FILE 'REGISTRY' ENTERED AT 08:54:54 ON 22 SEP 2005

FILE 'HCAPLUS' ENTERED AT 08:54:54 ON 22 SEP 2005

L2 TRA L1 1- RN : 221 TERMS

FILE 'REGISTRY' ENTERED AT 08:54:54 ON 22 SEP 2005

L3 221 SEA ABB=ON PLU=ON L2

FILE 'WPIX' ENTERED AT 08:55:04 ON 22 SEP 2005

L4 1 SEA ABB=ON PLU=ON US2004162278/PN OR (US2003-693327# OR  
GB2002-24919# OR US2002-428632#)/AP,PRN

FILE HOME

FILE HCAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Sep 2005 VOL 143 ISS 13

FILE LAST UPDATED: 21 Sep 2005 (20050921/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 21 SEP 2005 HIGHEST RN 863636-50-4

DICTIONARY FILE UPDATES: 21 SEP 2005 HIGHEST RN 863636-50-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

FILE WPIX

FILE LAST UPDATED: 20 SEP 2005 <20050920/UP>

MOST RECENT DERWENT UPDATE: 200560 <200560/DW>

DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,  
PLEASE VISIT:  
[http://www.stn-international.de/training\\_center/patents/stn\\_guide.pdf](http://www.stn-international.de/training_center/patents/stn_guide.pdf) <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE  
<http://thomsonderwent.com/coverage/latestupdates/> <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER  
GUIDES, PLEASE VISIT:  
<http://thomsonderwent.com/support/userguides/> <<<

>>> NEW! FAST-ALERTING ACCESS TO NEWLY-PUBLISHED PATENT  
DOCUMENTATION NOW AVAILABLE IN DERWENT WORLD PATENTS INDEX  
FIRST VIEW - FILE WPIFV.  
FOR FURTHER DETAILS: <http://www.thomsonderwent.com/dwpifv> <<<

>>> THE CPI AND EPI MANUAL CODES HAVE BEEN REVISED FROM UPDATE 200501.  
PLEASE CHECK:  
<http://thomsonderwent.com/support/dwpioref/reftools/classification/code-rev>  
FOR DETAILS. <<<

=> b hcap

FILE 'HCAPLUS' ENTERED AT 08:55:34 ON 22 SEP 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Sep 2005 VOL 143 ISS 13  
FILE LAST UPDATED: 21 Sep 2005 (20050921/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all 11 tot

L1 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN  
AN 2004:370921 HCAPLUS  
DN 140:391283  
ED Entered STN: 07 May 2004  
TI Preparation of triazoles as vasopressin receptor V1a antagonists for

treating of dysmenorrhea  
 IN Armour, Robert Duncan; Baxter, Andrew Douglas; Bryans, Justin Stephen;  
 Dack, Kevin Neil; Johnson, Patrick Stephen; Lewthwaite, Russell Andrew;  
 Newman, Julie; Rawson, David James; Ryckmans, Thomas  
 PA Pfizer Limited, UK; Pfizer Inc.  
 SO PCT Int. Appl., 122 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM C07D401-04  
 ICS C07D401-06; C07D401-14; C07D413-04; C07D413-06; C07D413-14;  
 A61K031-4196; A61P009-00; A61P007-00; A61P013-00; A61P025-00;  
 C07D403-12; C07D401-12; C07D405-14  
 CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))  
 Section cross-reference(s): 1, 63  
 FAN.CNT 1

|      | PATENT NO.  | KIND | DATE     | APPLICATION NO. | DATE         |
|------|---|------|----------|-----------------|--------------|
| PI   | WO 2004037809   | A1   | 20040506 | WO 2003-IB4587  | 20031014 <-- |
|      | W:  |      |          |                 |              |
|      | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, |      |          |                 |              |
|      | CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, |      |          |                 |              |
|      | GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, |      |          |                 |              |
|      | LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, |      |          |                 |              |
|      | PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, |      |          |                 |              |
|      | TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW                      |      |          |                 |              |
|      | RW:   |      |          |                 |              |
|      | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, |      |          |                 |              |
|      | KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, |      |          |                 |              |
|      | FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, |      |          |                 |              |
|      | BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  |      |          |                 |              |
|      | CA 2502932  | AA   | 20040506 | CA 2003-2502932 | 20031014 <-- |
|      | EP 1558598  | A1   | 20050803 | EP 2003-748487  | 20031014 <-- |
|      | R:  |      |          |                 |              |
|      | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, |      |          |                 |              |
|      | IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK      |      |          |                 |              |
|      | US 2004162278   | A1   | 20040819 | US 2003-693327  | 20031024 <-- |
| PRAI | GB 2002-24919   | A    | 20021025 | <--             |              |
|      | US 2002-428632P   | P    | 20021122 | <--             |              |
|      | WO 2003-IB4587  | W    | 20031014 |                 |              |

## CLASS

| PATENT NO.    | CLASS | PATENT FAMILY CLASSIFICATION CODES  |
|---------------|-------|---|
| WO 2004037809 | ICM   | C07D401-04  |
|               | ICS   | C07D401-06; C07D401-14; C07D413-04; C07D413-06;<br>C07D413-14; A61K031-4196; A61P009-00; A61P007-00;<br>A61P013-00; A61P025-00; C07D403-12; C07D401-12;<br>C07D405-14   |
| WO 2004037809 | ECLA  | C07D401/04+249B+211; C07D401/06+249B+211;<br>C07D401/12+249B+213; C07D401/14+249B+213+211;<br>C07D401/14+249B+239B+211; C07D401/14+249B+241B+211;<br>C07D401/14+249B+213+211+211;<br>C07D401/14+249B+213+211+207;<br>C07D401/14+249B+239B+211+211;<br>C07D401/14+249B+249+213+211;<br>C07D401/14+249B+213+213+211; C07D403/12+249B+239B;<br>C07D405/14+307B+249B+213+211;<br>C07D405/14+309+249B+213+211; C07D413/04+271+211;<br>C07D413/06+271+211; C07D413/14+271+213+211;<br>C07D413/14+271+213+211+211; C07D413/14+271+239B+211 <-- |
| CA 2502932    | ECLA  | C07D401/04+249B+211; C07D401/06+249B+211;<br>C07D401/12+249B+213; C07D401/14+249B+213+211;<br>C07D401/14+249B+213+211+207;<br>C07D401/14+249B+213+211+211;<br>C07D401/14+249B+213+213+211; C07D401/14+249B+239B+211;<br>C07D401/14+249B+239B+211+211; C07D401/14+249B+241B+211;<br>C07D401/14+249B+249+213+211; C07D403/12+249B+239B;<br>C07D405/14+307B+249B+213+211;<br>C07D405/14+309+249B+213+211; C07D413/04+271+211;  |

EP 1558598 ECLA C07D413/06+271+211; C07D413/14+271+213+211;  
C07D413/14+271+213+211+211; C07D413/14+271+239B+211 <--  
C07D401/04+249B+211; C07D401/06+249B+211;  
C07D401/12+249B+213; C07D401/14+249B+213+211;  
C07D401/14+249B+213+211+207;  
C07D401/14+249B+213+211+211;  
C07D401/14+249B+213+213+211; C07D401/14+249B+239B+211;  
C07D401/14+249B+239B+211+211; C07D401/14+249B+241B+211;  
C07D401/14+249B+249+213+211; C07D403/12+249B+239B;  
C07D405/14+307B+249B+213+211;  
C07D405/14+309+249B+213+211; C07D413/04+271+211;  
C07D413/06+271+211; C07D413/14+271+213+211;  
C07D413/14+271+213+211+211; C07D413/14+271+239B+211 <--  
US 2004162278 NCL 514/210.200  
ECLA C07D401/04+249B+211; C07D401/06+249B+211;  
C07D401/12+249B+213; C07D401/14+249B+213+211;  
C07D401/14+249B+213+211+207;  
C07D401/14+249B+213+211+211;  
C07D401/14+249B+213+213+211; C07D401/14+249B+239B+211;  
C07D401/14+249B+239B+211+211; C07D401/14+249B+241B+211;  
C07D401/14+249B+249+213+211; C07D403/12+249B+239B;  
C07D405/14+307B+249B+213+211;  
C07D405/14+309+249B+213+211; C07D413/04+271+211;  
C07D413/06+271+211; C07D413/14+271+213+211;  
C07D413/14+271+213+211+211; C07D413/14+271+239B+211 <--  
OS MARPAT 140:391283  
GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I [wherein R1 = cyclo/alkyl, (CH<sub>2</sub>)cW, (CH<sub>2</sub>)cZ(CH<sub>2</sub>)dW; W = alkyl, alkyloxy, CONH<sub>2</sub> and derivs., NH<sub>2</sub> and derivs., (un)substituted Ph, etc.; Z = O or S(O)g; g = 0-2; R<sub>2</sub> = Ph optionally fused to a 5- or 6-membered aryl or heteroaryl; Y = (CHR<sub>3</sub>)a; R<sub>3</sub> = independently H, alkyl, OH and derivs., etc.; X = (CH<sub>2</sub>)b; a, b = independently 0-1; c, d = 0-4; A = 4-, 5- or 6-membered saturated heterocyclyl, B = (un)substituted Ph, 4-, 5-, or 6-membered (un)saturated heterocyclyl; their pharmaceutically acceptable salts and solvates] were prepared as vasopressin receptor V1a antagonists for the treatment of dysmenorrhea. Thus, reacting oxadiazole II (preparation given) with (S)-1-phenylethylamine in the presence of anhydrous MgCl<sub>2</sub> at 150° gave triazole III. I showed K<sub>i</sub> values < 500 nM in a V1a filter binding assay.

ST triazole prepn V1a antagonist dysmenorrhea

IT Blood vessel, disease  
(Raynaud's phenomenon, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT Vasopressin receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(V1a, antagonist; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT Behavior  
(aggresive; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT Appetite  
(anorexia nervosa, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT Antiarteriosclerotics  
(antiatherosclerotics; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT Ischemia  
(cardiac, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT Nervous system, disease

(central; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT Mental disorder  
(cognitive, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT Mental disorder  
(depression, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT Urogenital tract  
(disease, infection, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT Sexual behavior  
(disorder, treatment of male and female; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT Cognition  
(disorder, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT Uterus, disease  
(endometriosis, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT Heart, disease

Kidney, disease  
(failure, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT Reproductive tract, disease  
(female, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT Embryo, animal, disease  
(fetus, intrauterine growth retardation, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT Spinal cord, disease  
(injury, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT Heart, disease  
(ischemia, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT Diabetes mellitus  
(non-insulin-dependent, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT Mental disorder  
(obsession-compulsion, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT Contraceptives

Drug delivery systems  
(oral; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT Sexual behavior  
(premature ejaculation, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT Parturition  
(premature, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT Anti-Alzheimer's agents

Anti-ischemic agents

Antiasthmatics

Antidepressants

Antidiabetic agents

Antiemetics

Antiglaucoma agents

Antihypertensives

Antiobesity agents

Antitumor agents

Anxiolytics

Cardiovascular agents

Cognition enhancers

Diuretics

Human  
Hypnotics and Sedatives  
Thrombolytics  
(preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT Injury  
(spinal cord, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT Ischemia  
(treatment of cerebrovascular; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT Alzheimer's disease  
Anxiety  
Asthma  
Atherosclerosis  
Calculi, urinary  
Cardiovascular system, disease  
Cataract  
Cirrhosis  
Cushing's syndrome  
Diabetes mellitus  
Digestive tract, disease  
Dysmenorrhea  
Edema  
Glaucoma (disease)  
Heart, disease  
Hypertension  
Ischemia  
Kidney  
Kidney, disease  
Lung, disease  
Lung, neoplasm  
Micturition  
Motion sickness  
Neoplasm  
Nervous system agents  
Obesity  
Sleep disorders  
Thrombosis  
Vomiting  
(treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT Infection  
(urogenital, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT 685827-43-4P, 4-[4-Benzyl-5-[4-(methanesulfonyl)piperazin-1-ylmethyl]-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl  
685827-47-8P, 4-(4-Benzyl-5-[(morpholin-4-yl)methyl]-4H-[1,2,4]triazol-3-yl)-3'-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(V1A receptor antagonist, V1a receptor antagonist; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT 685827-36-5P, 4-[4-(3-Chlorobenzyl)-5-methyl-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-69-4P, 4-[4-Benzyl-5-(2-oxa-5-azabicyclo[2.2.1]hept-5-ylmethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(V1A receptor antagonist; preparation of triazoles as V1a receptor antagonists for treatment of dysmenorrhea)

IT 685827-26-3P, Benzyl 4-[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl]piperazine-1-carboxylate

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(V1a receptor antagonist, intermediate; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT 685826-99-7P, (S)-4-[5-Butyl-4-(1-phenylethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-00-3P, 2-[4-(4-Benzyl-5-isobutyl-4H-[1,2,4]triazol-3-yl)piperidin-1-yl]pyrimidine 685827-01-4P, (S)-4-[5-Methyl-4-(1-phenylethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-02-5P, 4-(4-Benzyl-5-butyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-03-6P, 2-[4-(4-Benzyl-5-isopropyl-4H-[1,2,4]triazol-3-yl)piperidin-1-yl]pyrimidine 685827-04-7P, 2-[4-(4-Benzyl-5-cyclopropyl-4H-[1,2,4]triazol-3-yl)piperidin-1-yl]pyrimidine 685827-05-8P, (S)-2-[4-[5-Methyl-4-(1-phenylpropyl)-4H-[1,2,4]triazol-3-yl]piperidin-1-yl]pyrimidine 685827-06-9P, 2-[4-(4-Benzyl-5-propyl-4H-[1,2,4]triazol-3-yl)piperidin-1-yl]pyrimidine 685827-07-0P, 2-[4-[4-Benzyl-5-(2-chlorophenoxy)methyl]-4H-[1,2,4]triazol-3-yl]piperidin-1-yl]pyrimidine 685827-08-1P, 2-[4-(4-Benzyl-5-butyl-4H-[1,2,4]triazol-3-yl)piperidin-1-yl]pyrimidine 685827-09-2P, (S)-2-[4-[5-Methyl-4-(1-phenylethyl)-4H-[1,2,4]triazol-3-yl]piperidin-1-yl]pyrimidine 685827-10-5P, 2-[4-[4-Benzyl-5-(4-fluorophenoxy)methyl]-4H-[1,2,4]triazol-3-yl]piperidin-1-yl]pyrimidine 685827-11-6P, 2-[4-[5-Methyl-4-(3-methylbenzyl)-4H-[1,2,4]triazol-3-yl]piperidin-1-yl]pyrimidine 685827-12-7P, (S)-2-[4-[5-Methyl-4-(1-phenylethyl)-4H-[1,2,4]triazol-3-ylmethyl]piperidin-1-yl]pyrimidine 685827-13-8P, 2-[4-[4-(3-Fluorobenzyl)-5-methyl-4H-[1,2,4]triazol-3-yl]piperidin-1-yl]pyrimidine 685827-14-9P, 4-(4-Benzyl-5-[(morpholin-4-yl)methyl]-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-15-0P, 4-[4-Benzyl-5-[(benzyloxy)methyl]-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-16-1P, 4-(4-Benzyl-5-methyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-17-2P, (R)-2-[3-Methyl-5-[1-(pyrimidin-2-yl)piperidin-4-yl]-[1,2,4]triazol-4-yl]-2-phenylethanol 685827-18-3P, 2-[4-(4-Benzyl-5-methyl-4H-[1,2,4]triazol-3-yl)piperidin-1-yl]-4-methylpyrimidine 685827-19-4P, 2-[4-(4-Benzyl-5-methyl-4H-[1,2,4]triazol-3-yl)piperidin-1-yl]pyrimidine 685827-20-7P, 4-(4-Benzyl-5-methyl-4H-[1,2,4]triazol-3-yl)-1-phenylpiperidine 685827-21-8P, 2-[4-(4-Benzyl-5-methyl-4H-[1,2,4]triazol-3-yl)piperidin-1-yl]pyrazine 685827-22-9P, 4-(4-Benzyl-5-[(piperidin-1-yl)methyl]-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-23-0P, (S)-4-[4-(1-Phenylethyl)-5-[(piperidin-1-yl)methyl]-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-24-1P, 4-[4-Benzyl-5-(4-methoxypiperidin-1-ylmethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-25-2P, (S)-4-[5-(4-Methoxypiperidin-1-ylmethyl)-4-(1-phenylethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-27-4P, 4-[4-Benzyl-5-[[2-(morpholin-4-yl)ethoxy]methyl]-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-28-5P, 4-[4-Benzyl-5-((3R)-3-methoxypyrrolidin-1-ylmethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-29-6P 685827-30-9P 685827-31-0P 685827-32-1P 685827-33-2P 685827-34-3P 685827-35-4P 685827-37-6P, N-Benzyl-2-[4-benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-yl]acetamide 685827-38-7P, 2-[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethoxy]ethylamine 685827-39-8P, N-[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl]ethylamine 685827-40-1P, [4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl](2-methoxyethyl)amine 685827-41-2P, [4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl](3-methoxypropyl)amine 685827-42-3P, 1-[4-[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl]piperazin-1-yl]ethanone 685827-44-5P, N-[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl]methanesulfonamide 685827-45-6P,



[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl](2-methoxyethyl)methylamine 685827-46-7P,  
 [4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl](3-methoxypropyl)methylamine 685827-48-9P,  
 4-(4-Benzyl-5-[(morpholin-4-yl)methyl]-4H-[1,2,4]triazol-3-yl)-3'-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-49-0P,  
 4-(4-Benzyl-5-[(morpholin-4-yl)methyl]-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-3'-carbonitrile 685827-50-3P,  
 4-(4-Benzyl-5-[(morpholin-4-yl)methyl]-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-3'-carboxylic acid amide 685827-51-4P,  
 (S)-4-[[4-(1-Phenylethyl)-5-[4-(pyridin-2-yl)piperazin-1-ylmethyl]-4H-[1,2,4]triazol-3-yl)methyl]morpholine trihydrochloride 685827-52-5P,  
 (S)-4-[[4-(1-Phenylethyl)-5-[[4-(pyrimidin-2-yl)piperazin-1-yl]methyl]-4H-[1,2,4]triazol-3-yl)methyl]morpholine trihydrochloride 685827-53-6P,  
 1-[[4-Benzyl-5-[1-(pyrimidin-2-yl)piperidin-4-yl]-4H-[1,2,4]triazol-3-yl)methyl]piperidin-3-ol 685827-54-7P, (R)-2-[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-yl]pyrrolidine-1-carboxylic acid tert-butyl ester 685827-55-8P, (R)-4-[4-Benzyl-5-[[[(tetrahydrofuran-3-yl)oxy]methyl]-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-56-9P, (S)-4-[4-Benzyl-5-[[[(tetrahydrofuran-3-yl)oxy]methyl]-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-57-0P, [[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl]methylamino]acetic acid tert-butyl ester 685827-58-1P,  
 4-[4-Benzyl-5-(tetrahydropyran-4-ylmethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-59-2P, 4-[4-Benzyl-5-(tetrahydrofuran-2-yl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-60-5P, 4-[4-Benzyl-5-(ethoxymethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-61-6P, 4-[4-Benzyl-5-(2-methoxyethoxymethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-62-7P,  
 [4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethoxy]acetic acid tert-butyl ester 685827-63-8P,  
 N-Benzyl-2-[4-benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethoxy]acetamide 685827-64-9P, 4-[4-Benzyl-5-[(methylsulfanyl)methyl]-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-65-0P, 4-(4-Benzyl-5-[(pyrazol-1-yl)methyl]-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-66-1P, 4-(4-Benzyl-5-[[[1,2,3]triazol-2-yl)methyl]-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-67-2P, 4-(4-Benzyl-5-[1,2,3]triazol-1-ylmethyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-68-3P,  
 4-[4-Benzyl-5-(pyridin-4-yloxy)methyl]-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(V1a receptor antagonist; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT 7440-23-5, Sodium, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study) (hyponatremia; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT 474707-30-7P, (3R)-3-Methoxypyrrolidine hydrochloride 549532-08-3P, (3R)-3-Methoxypyrrolidine-1-carboxylic acid tert-butyl ester 550371-69-2P, (3S)-3-Methoxypyrrolidine-1-carboxylic acid tert-butyl ester 685827-70-7P, 3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-carboxylic acid 685827-71-8P, N'-Butyryl-1-(Pyrimidin-2-yl)piperidine-4-carboxylic hydrazide 685827-72-9P 685827-73-0P 685827-74-1P 685827-75-2P 685827-76-3P 685827-77-4P 685827-78-5P 685827-79-6P 685827-80-9P, N'-Pentanoyl-3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-carboxylic hydrazide 685827-81-0P, N'-Acetyl-3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-carboxylic hydrazide 685827-82-1P, N'-[2-(Morpholin-4-yl)acetyl]-3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-carboxylic hydrazide 685827-83-2P, 1-(Pyrimidin-2-yl)piperidine-4-carboxylic hydrazide monohydrochloride 685827-84-3P,

N'-(3-Methylbutyryl)-1-(pyrimidin-2-yl)piperidine-4-carboxylic hydrazide  
685827-86-5P, 2-[4-(5-Isobutyl-[1,3,4]oxadiazol-2-yl)piperidin-1-  
yl]pyrimidine 685827-87-6P 685827-88-7P 685827-89-8P 685827-90-1P  
685827-91-2P 685827-92-3P 685827-93-4P 685827-94-5P 685827-95-6P  
685827-96-7P 685827-97-8P, 2-[4-(5-Methyl-[1,3,4]oxadiazol-2-  
yl)piperidin-1-yl]pyrimidine 685827-98-9P, 4-(4-Benzyl-5-methyl-4H-  
[1,2,4]triazol-3-yl)piperidine-1-carboxylic acid tert-butyl ester  
685827-99-0P, 4-(4-Benzyl-5-methyl-4H-[1,2,4]triazol-3-yl)piperidine  
monohydrochloride 685828-00-6P, 4-[(5-Methyl-[1,3,4]oxadiazol-2-  
yl)methyl]piperidine monohydrochloride 685828-01-7P,  
2-[4-[(5-Methyl-[1,3,4]oxadiazol-2-yl)methyl]piperidin-1-yl]pyrimidine  
685828-02-8P, 3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-carboxylic  
hydrazide 685828-03-9P, 1-(Pyrimidin-2-yl)piperidine-4-carboxylic  
hydrazide 685828-04-0P, N'-(2-Benzoyloxyacetyl)-3,4,5,6-Tetrahydro-2H-  
[1,2']bipyridinyl-4-carboxylic hydrazide 685828-05-1P,  
4-[5-[(Benzoyloxy)methyl]-[1,3,4]oxadiazol-2-yl]-3,4,5,6-tetrahydro-2H-  
[1,2']bipyridinyl 685828-06-2P, N'-(2-Chloroacetyl)-3,4,5,6-Tetrahydro-  
2H-[1,2']bipyridinyl-4-carboxylic hydrazide 685828-07-3P,  
N'-(2-Chloroacetyl)-1-(pyrimidin-2-yl)piperidine-4-carboxylic hydrazide  
685828-08-4P, 4-(5-Chloromethyl-[1,3,4]oxadiazol-2-yl)-3,4,5,6-tetrahydro-  
2H-[1,2']bipyridinyl 685828-09-5P, 2-[4-(5-Chloromethyl-[1,3,4]oxadiazol-  
2-yl)piperidin-1-yl]pyrimidine 685828-10-8P, 4-[5-[(Piperidin-1-  
yl)methyl]-[1,3,4]oxadiazol-2-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl  
685828-11-9P 685828-12-0P 685828-13-1P, 4-[5-[[2-(Morpholin-4-  
yl)ethoxy]methyl]-[1,3,4]oxadiazol-2-yl]-3,4,5,6-tetrahydro-2H-  
[1,2']bipyridinyl 685828-14-2P, 3-Oxo-3-[2-[(3,4,5,6-tetrahydro-2H-  
[1,2']bipyridin-4-yl)carbonyl]hydrazino]propionic acid tert-butyl ester  
685828-15-3P, [5-(3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-  
yl)[1,3,4]oxadiazol-2-yl]acetic acid tert-butyl ester 685828-16-4P,  
(3S)-3-Methoxypyrrolidine hydrochloride 685828-17-5P 685828-18-6P  
685828-19-7P 685828-20-0P 685828-21-1P 685828-22-2P 685828-23-3P  
685828-24-4P 685828-25-5P, Ethyl-[5-(3,4,5,6-Tetrahydro-2H-  
[1,2']bipyridinyl-4-yl)-[1,3,4]oxadiazol-2-ylmethyl]amine 685828-26-6P,  
[2-[5-(3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-yl)-[1,3,4]oxadiazol-2-  
ylmethoxy]ethyl]carbamic acid tert-butyl ester 685828-27-7P,  
[5-(3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-yl)-[1,3,4]oxadiazol-2-  
ylmethyl]carbamic acid tert-butyl ester 685828-28-8P 685828-29-9P  
685828-30-2P 685828-31-3P, [4-Benzyl-5-(3,4,5,6-tetrahydro-2H-  
[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl]carbamic acid  
tert-butyl ester 685828-32-4P 685828-33-5P 685828-34-6P  
685828-35-7P, [2-[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-  
yl)-4H-[1,2,4]triazol-3-ylmethoxy]ethyl]carbamic acid tert-butyl ester  
685828-36-8P 685828-37-9P, 4-(4-Benzyl-5-[(piperazin-1-yl)methyl]-4H-  
[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl  
685828-38-0P 685828-39-1P, 4-(5-Chloromethyl-[1,3,4]oxadiazol-2-  
yl)piperidine-1-carboxylic acid tert-butyl ester 685828-40-4P,  
4-[5-[(Morpholin-4-yl)methyl]-[1,3,4]oxadiazol-2-yl]piperidine-1-  
carboxylic acid tert-butyl ester 685828-41-5P, 4-(4-Benzyl-5-morpholin-4-  
ylmethyl-4H-[1,2,4]triazol-3-yl)piperidine-1-carboxylic acid tert-butyl  
ester 685828-42-6P, 4-[[4-Benzyl-5-(piperidin-4-yl)-4H-[1,2,4]triazol-3-  
yl)methyl]morpholine 685828-43-7P 685828-44-8P, 4-[(5-Chloromethyl-  
[1,3,4]oxadiazol-2-yl)methyl]morpholine 685828-45-9P,  
4-[5-[4-(Pyridin-2-yl)piperazin-1-ylmethyl]-[1,3,4]oxadiazol-2-  
yl)methyl]morpholine 685828-46-0P, 4-[5-[4-(Pyrimidin-2-yl)piperazin-1-  
ylmethyl]-[1,3,4]oxadiazol-2-yl)methyl]morpholine 685828-47-1P,  
1-[5-[1-(Pyrimidin-2-yl)piperidin-4-yl]-[1,3,4]oxadiazol-2-  
yl)methyl]piperidin-3-ol 685828-48-2P, (R)-2-[N'-[(3,4,5,6-Tetrahydro-2H-  
[1,2']bipyridin-4-yl)carbonyl]hydrazinocarbonyl]pyrrolidine-1-carboxylic  
acid tert-butyl ester 685828-50-6P, (R)-2-[5-(3,4,5,6-Tetrahydro-2H-  
[1,2']bipyridinyl-4-yl)-[1,3,4]oxadiazol-2-yl]pyrrolidine-1-carboxylic  
acid tert-butyl ester 685828-51-7P, (R)-4-[5-[(Tetrahydrofuran-3-  
yl)oxy]methyl]-[1,3,4]oxadiazol-2-yl]-3,4,5,6-tetrahydro-2H-  
[1,2']bipyridinyl 685828-52-8P, (S)-4-[5-[(Tetrahydrofuran-3-  
yl)oxy]methyl]-[1,3,4]oxadiazol-2-yl]-3,4,5,6-tetrahydro-2H-  
[1,2']bipyridinyl 685828-53-9P, [Methyl[5-(3,4,5,6-tetrahydro-2H-  
[1,2']bipyridinyl-4-yl)[1,3,4]oxadiazol-2-ylmethyl]amino]acetic acid

tert-butyl ester 685828-54-0P, N'-[(3,4,5,6-Tetrahydro-2H-[1,2']bipyridin-4-yl)carbonyl]tetrahydrofuran-2-carboxylic hydrazide  
 685828-55-1P, 4-[5-(Tetrahydrofuran-2-yl)-[1,3,4]oxadiazol-2-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685828-56-2P, 3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-carboxylic acid N'-(2-tetrahydropyran-4-ylacetyl)hydrazide 685828-57-3P, 4-[5-(Tetrahydropyran-4-ylmethyl)-[1,3,4]oxadiazol-2-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl  
 685828-58-4P, 4-(5-Ethoxymethyl-[1,3,4]oxadiazol-2-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685828-59-5P, 4-[5-(2-Methoxyethoxymethyl)-[1,3,4]oxadiazol-2-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl  
 685828-60-8P, [5-(3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-yl)[1,3,4]oxadiazol-2-ylmethoxy]acetic acid tert-butyl ester  
 685828-62-0P, 4-[5-[(Pyrazol-1-yl)methyl]-[1,3,4]oxadiazol-2-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685828-63-1P 685828-64-2P,  
 4-[5-[[[1,2,3]Triazol-1-yl)methyl]-[1,3,4]oxadiazol-2-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685828-65-3P, 4-[5-(Pyridin-4-yloxy)methyl]-[1,3,4]oxadiazol-2-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of triazoles as V1a receptor antagonists for treatment of dysmenorrhea)

IT 79-30-1, Isobutyryl chloride 98-91-9, Benzenecarbothioic acid  
 108-12-3, 3-Methylbutyryl chloride 108-86-1, Bromobenzene, reactions  
 109-02-4, 4-Methylmorpholine 109-09-1, 2-Chloropyridine 109-85-3  
 110-91-8, Morpholine, reactions 123-75-1, Pyrrolidine, reactions  
 288-13-1, 1H-Pyrazole 288-35-7, 2H-[1,2,3]Triazole 541-16-2,  
 tert-Butyl malonate 622-40-2, 2-(Morpholin-4-yl)ethanol 626-64-2,  
 4-Hydroxypyridine 770-17-2 870-46-2, Hydrazinecarboxylic acid  
 tert-butyl ester 1722-12-9, 2-Chloropyrimidine 2627-86-3,  
 ((S)-(-)-1-Phenylethyl)amine 3430-17-9, 2-Bromo-3-methylpyridine  
 3538-65-6, Butyric acid hydrazide 4595-60-2, 2-Bromopyrimidine  
 5332-73-0 5616-81-9 6602-54-6, 2-Chloro-3-cyanopyridine 6859-99-0,  
 Piperidin-3-ol 14508-49-7, 2-Chloropyrazine 16874-33-2,  
 Tetrahydrofuran-2-carboxylic acid 19810-31-2 26690-80-2, tert-Butyl  
 N-(2-hydroxyethyl)carbamate 38291-82-6, Pentanoic acid hydrazide  
 40499-83-0, 3-Hydroxypyrrolidine 50595-15-8 51957-36-9,  
 1-(2-Pyrimidyl)piperidine 56613-80-0, (R)-(-)-2-Amino-2-phenylethanol  
 57260-71-6 65753-47-1, 2-Chloro-3-trifluoromethylpyridine 68654-52-4,  
 1-(2-Pyridyl)piperidine 86087-23-2, (S)-Tetrahydrofuran-3-ol  
 86087-24-3, (R)-Tetrahydrofuran-3-ol 101469-92-5, (3S)-3-Hydroxypyrrolidine-1-carboxylic acid tert-butyl ester 109431-87-0,  
 (3R)-3-Hydroxypyrrolidine-1-carboxylic acid tert-butyl ester  
 111247-60-0, 1-(Pyrimidin-2-yl)piperidine-4-carboxylic acid ethyl ester  
 120099-60-7 120099-61-8 130645-48-6, 2-Bromo-4-methylpyrimidine  
 154348-19-3, 3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-carboxylic acid  
 ethyl ester 187834-88-4, 4-(Hydrazinocarbonyl)piperidine-1-carboxylic  
 acid tert-butyl ester 280110-69-2, 4-(5-Methyl-[1,3,4]oxadiazol-2-yl)piperidine-1-carboxylic acid tert-butyl ester 303144-44-7,  
 1-(Pyrimidin-2-yl)piperidine-4-carboxylic acid 547716-11-0 685827-85-4  
 685828-49-3 685828-61-9, 4-[5-[(Methylsulfanyl)methyl]-[1,3,4]oxadiazol-2-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of triazoles as V1a receptor antagonists for treatment of dysmenorrhea)

=> b wpix;d all 14 tot  
 FILE 'WPIX' ENTERED AT 08:55:54 ON 22 SEP 2005  
 COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE LAST UPDATED: 20 SEP 2005 <20050920/UP>  
 MOST RECENT DERWENT UPDATE: 200560 <200560/DW>  
 DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,

Search done by Noble Jarrell

## PLEASE VISIT:

[http://www.stn-international.de/training\\_center/patents/stn\\_guide.pdf](http://www.stn-international.de/training_center/patents/stn_guide.pdf) <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE  
<http://thomsonderwent.com/coverage/latestupdates/> <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER  
 GUIDES, PLEASE VISIT:  
<http://thomsonderwent.com/support/userguides/> <<<

>>> NEW! FAST-ALERTING ACCESS TO NEWLY-PUBLISHED PATENT  
 DOCUMENTATION NOW AVAILABLE IN DERWENT WORLD PATENTS INDEX  
 FIRST VIEW - FILE WPIFV.  
 FOR FURTHER DETAILS: <http://www.thomsonderwent.com/dwpifv> <<<

>>> THE CPI AND EPI MANUAL CODES HAVE BEEN REVISED FROM UPDATE 200501.  
 PLEASE CHECK:  
<http://thomsonderwent.com/support/dwpioref/reftools/classification/code-revision/>  
 FOR DETAILS. <<<  
 'BIX BI,ABEX' IS DEFAULT SEARCH FIELD FOR 'WPIX' FILE

L4 ANSWER 1 OF 1 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN  
 AN 2004-389824 [36] WPIX  
 DNC C2004-146105  
 TI New triazole compounds are arginine vasopressin V1a receptor antagonists  
 useful to treat Alzheimer's disease, anorexia nervosa, anxiety disorder,  
 asthma, atherosclerosis, cardiac failure, cardiovascular disease and  
 cataract.  
 DC B03  
 IN ARMOUR, R D; BAXTER, A D; BRYANS, J S; DACK, K N; JOHNSON, P S;  
 LEWTHWAITE, R A; NEWMAN, J; RAWSON, D J; RYCKMANS, T; ARMOUR, D R  
 PA (PFIZ) PFIZER INC; (PFIZ) PFIZER LTD  
 CYC 104  
 PI WO 2004037809 A1 20040506 (200436)\* EN 122 C07D401-04  
 RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS  
 LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW  
 W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK  
 DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR  
 KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL  
 PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU  
 ZA ZM ZW  
 US 2004162278 A1 20040819 (200455) A61K031-454 <--  
 AU 2003267791 A1 20040513 (200468) C07D401-04  
 EP 1558598 A1 20050803 (200551) EN C07D401-04  
 R: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LT LU LV  
 MC MK NL PT RO SE SI SK TR  
 BR 2003015676 A 20050906 (200560) C07D401-04  
 ADT WO 2004037809 A1 WO 2003-IB4587 20031014; US 2004162278 A1  
 Provisional US 2002-428632P 20021122, US 2003-693327  
 20031024; AU 2003267791 A1 AU 2003-267791 20031014; EP 1558598 A1 EP  
 2003-748487 20031014, WO 2003-IB4587 20031014; BR 2003015676 A BR  
 2003-15676 20031014, WO 2003-IB4587 20031014  
 FDT AU 2003267791 A1 Based on WO 2004037809; EP 1558598 A1 Based on WO  
 2004037809; BR 2003015676 A Based on WO 2004037809  
 PRAI GB 2002-24919 20021025  
 IC ICM A61K031-454; C07D401-04  
 ICS A61K031-4196; A61P007-00; A61P009-00; A61P013-00; A61P025-00;  
 C07D401-06; C07D401-12; C07D401-14; C07D403-12; C07D405-14;  
 C07D413-04; C07D413-06; C07D413-14  
 AB WO2004037809 A UPAB: 20040608  
 NOVELTY - Triazole compounds (I) and their salts and solvates are new.  
 DETAILED DESCRIPTION - Triazole compounds of formula (I) and their  
 salts and solvates are new.  
 R1 = 1-6C alkyl, (CH2)C'-(3-8C cycloalkyl), (CH2)C'-W or

(CH<sub>2</sub>)c'-Z-(CH<sub>2</sub>)d-W;  
 W = 1-6C alkyl, 1-6C alkyloxy, CO<sub>2</sub>(1-6C alkyl), CONR<sub>4</sub>R<sub>5</sub>, NR<sub>4</sub>R<sub>5</sub>,  
 het<sub>2</sub>, het<sub>3</sub> or phenyl (optionally substituted with halo, CF<sub>3</sub>, OCF<sub>3</sub>, R<sub>3</sub>,  
 OR<sub>3</sub>, CO<sub>2</sub>R<sub>3</sub>, CONR<sub>4</sub>R<sub>5</sub>, CN, SO<sub>2</sub>NR<sub>4</sub>R<sub>5</sub> and/or NR<sub>3</sub>SO<sub>2</sub>Me);  
 Q = (CH<sub>2</sub>)b;  
 Q<sub>1</sub> = (CHR<sub>7</sub>)a;  
 Z = O or S(O)g;  
 g = 0-2;  
 R<sub>2</sub> = a phenyl (optionally fused to a 5-6 membered aryl or  
 heterocyclic which may contain one or more heteroatoms of N, O or S (the  
 phenyl and the optionally fused group is optionally substituted);  
 Ring A = 4-6 membered saturated heterocyclic containing one N;  
 Ring B = phenyl or het<sub>1</sub> (optionally substituted);  
 R<sub>7</sub> = H, 1-6C alkyl, OR<sub>3</sub>, (CH<sub>2</sub>)e-R<sub>3</sub> or (CH<sub>2</sub>)fO-(CH<sub>2</sub>)e-R<sub>3</sub>;  
 R<sub>3</sub> = 1-6C alkyl (optionally substituted by Y), (CH<sub>2</sub>)g-(3-8C  
 cycloalkyl), phenyl, benzyl, pyridyl, pyrimidyl or H; either  
 R<sub>4</sub>, R<sub>5</sub> = H, 1-6C alkyl (optionally substituted with 1-6C alkyloxy),  
 (CH<sub>2</sub>)gCO<sub>2</sub>-(1-6C alkyl), SO<sub>2</sub>Me, (CH<sub>2</sub>)g-(3-8C cycloalkyl), SO<sub>2</sub>Me, phenyl,  
 benzyl, pyridyl or pyrimidyl; or  
 NR<sub>4</sub>R<sub>5</sub> = heterocyclic from 3-8 atoms;  
 Y = NR<sub>4</sub>R<sub>5</sub>, het<sub>4</sub> or phenyl (optionally substituted with halo, CF<sub>3</sub>,  
 OCF<sub>3</sub>, R<sub>4</sub>, OR<sub>4</sub>, CO<sub>2</sub>R<sub>4</sub>, CONR<sub>4</sub>R<sub>5</sub>, CN, SO<sub>2</sub>NR<sub>4</sub>R<sub>5</sub>, NR<sub>4</sub>SO<sub>2</sub>Me or NR<sub>4</sub>R<sub>5</sub>);  
 het<sub>1</sub> = 4-6 membered optionally saturated, heterocyclic containing  
 one N (but which may also contain one or more O or S atoms);  
 het<sub>2</sub> = 4-6 membered optionally saturated, heterocyclic containing at  
 least one N (but which may also contain one or more O or S atoms)  
 (optionally substituted);  
 het<sub>3</sub> = 4-7 membered optionally saturated, heterocyclic containing  
 one O (but which may also contain one or more N or S atoms) (optionally  
 substituted);  
 het<sub>4</sub> = 4-7 membered optionally saturated heterocyclic containing one  
 N (but which may also contain one or more O or S atoms) (optionally  
 substituted);  
 substituents for R<sub>2</sub>, Ring B, het<sub>1</sub>, het<sub>2</sub>, het<sub>3</sub>, het<sub>4</sub> = halo, CF<sub>3</sub>,  
 OCF<sub>3</sub>, R<sub>3</sub>, (CH<sub>2</sub>)e-SO<sub>2</sub>Me, (CH<sub>2</sub>)e-OR<sub>3</sub>, (CH<sub>2</sub>)e-CO<sub>2</sub>R<sub>3</sub>, (CH<sub>2</sub>)e-CONR<sub>4</sub>R<sub>5</sub>,  
 (CH<sub>2</sub>)e-CN, (CH<sub>2</sub>)e-SO<sub>2</sub>NR<sub>4</sub>R<sub>5</sub>, (CH<sub>2</sub>)e-NR<sub>3</sub>SO<sub>2</sub>Me, (CH<sub>2</sub>)e-COR<sub>3</sub>, (CH<sub>2</sub>)e-OCOR<sub>3</sub>,  
 (CH<sub>2</sub>)e-NHCOR<sub>3</sub>, (CH<sub>2</sub>)e-NR<sub>3</sub>COR<sub>6</sub> or (CH<sub>2</sub>)eNR<sub>4</sub>R<sub>5</sub>;  
 R<sub>6</sub> = 1-6C alkyl (optionally substituted by Y), (CH<sub>2</sub>)g'-(3-8C  
 cycloalkyl), phenyl, benzyl, pyridyl, pyrimidyl or H;  
 a, b = 0-1;  
 c', d, e, g' = 0-4; and  
 f = 1-4.

Provided that:

- (1) a + b cannot equal 0;
- (2) when R<sub>1</sub> is (CH<sub>2</sub>)c-Z-(CH<sub>2</sub>)d-W and W represents NR<sub>4</sub>R<sub>5</sub> or any N  
 linked heterocyclic group, then d must not be 0 or 1;
- (3) when R<sub>2</sub> is a phenyl group substituted by (CH<sub>2</sub>)eOR<sub>3</sub>, (CH<sub>2</sub>)e-CO<sub>2</sub>R<sub>3</sub>  
 or (CH<sub>2</sub>)eOCOR<sub>3</sub>, het<sub>1</sub> and/or het<sub>2</sub> are substituted by (CH<sub>2</sub>)eOR<sub>3</sub>,  
 (CH<sub>2</sub>)e-CO<sub>2</sub>R<sub>3</sub> or (CH<sub>2</sub>)eOCOR<sub>3</sub>, R<sub>7</sub> is OR<sub>3</sub> or (CH<sub>2</sub>)fO-(CH<sub>2</sub>)e-R<sub>3</sub> and e is 0, W  
 is phenyl substituted with OR<sub>3</sub> or CO<sub>2</sub>R<sub>3</sub>, R<sub>3</sub> is alkyl substituted with Y  
 and Y is NR<sub>4</sub>R<sub>5</sub> or an N-linked het<sub>3</sub>, then R<sub>3</sub> must be 2-6C alkyl substituted  
 with Y.

INDEPENDENT CLAIMS are also included for

- (1) an intermediate oxadiazole of formula (II); and
- (2) use of an arginine vasopressin V<sub>1a</sub> antagonist in combination with  
 an oral contraceptive for the treatment of dysmenorrhoea.

ACTIVITY - Neuroprotective; Nootropic; Anabolic; Eating-Disorders-  
 Gen.; Tranquilizer; Antiasthmatic; Antiarteriosclerotic; Cardiant;  
 Cardiovascular-Gen.; Ophthalmological; CNS-Gen.; Cerebroprotective;  
 Vasotropic; Hepatotropic; Endocrine-Gen.; Antidepressant; Antidiabetic;  
 Analgesic; Gynecological; Antiinflammatory; Antiemetic; Cytostatic;  
 Gastrointestinal-Gen.; Antidiuretic; Nephrotropic; Anorectic; Hypotensive;  
 Tocolytic; Respiratory-Gen.; Hypnotic; Vulnerary; Thrombolytic;  
 Antimicrobial; Urothatic.

MECHANISM OF ACTION - Arginine vasopressin V<sub>1a</sub> receptor antagonist.

(I) were tested for their arginine vasopressin V<sub>1a</sub> receptor antagonistic

activity in CHO cells using V1a filter binding assay. The inhibitory constant (Ki) of 4-(4-benzyl-5-(4-methoxy-piperidin-1-ylmethyl)-4H-(1,2,4)triazol-3-yl)-3,4,5,6-tetrahydro-2H-(1,2')bipyridinyl was 4.5 nM.

USE - (I) are used to treat aggression, Alzheimer's disease, anorexia nervosa, anxiety disorder, asthma, atherosclerosis, cardiac failure, cardiovascular disease, cataract, central nervous system disease, cerebrovascular ischemia, cirrhosis, cognitive disorder, Cushing's disease, depression, diabetes mellitus, dysmenorrhea, edema, emesis, endometriosis, gastrointestinal disease, glaucoma, gynecological disease, heart disease, hypertension, hyponatremia, intrauterine growth retardation, ischemia, ischemic heart disease, lung tumor, micturition disorder, mittleschmerz, motion sickness, neoplasm, nephrotoxicity, non-insulin dependent diabetes, obesity, obsessive/compulsive disorder, ocular hypertension, premature ejaculation, premature labor, pulmonary disease, Raynaud's disease, renal disease, renal failure, male and female sexual dysfunction, sleep disorder, spinal cord injury, thrombosis, urogenital tract infection and urolithiasis (claimed).

ADVANTAGE - (I) are potent, stable and have a long duration of action, a broad range of activity and few side effects.

Dwg.0/0

FS CPI  
FA AB; GI; DCN  
MC CPI: B06-H; B07-D13; B07-E04; B14-C03; B14-D01; B14-E05; B14-E11; B14-E12;  
B14-F02B; B14-F02D1; B14-F04; B14-F07; B14-H01B; B14-J01; B14-K01;  
B14-L06; B14-N03; B14-N07; B14-N10; B14-N14; B14-N16; B14-P02;  
B14-S04

=> b home

FILE 'HOME' ENTERED AT 08:55:58 ON 22 SEP 2005

=>

=> d his full

(FILE 'HOME' ENTERED AT 08:52:27 ON 22 SEP 2005)

FILE 'HCAPLUS' ENTERED AT 08:52:42 ON 22 SEP 2005

L1 1 SEA ABB=ON PLU=ON US2004162278/PN OR (US2003-693327# OR  
GB2002-24919# OR US2002-428632#)/AP,PRN

FILE 'REGISTRY' ENTERED AT 08:54:54 ON 22 SEP 2005

L2 FILE 'HCAPLUS' ENTERED AT 08:54:54 ON 22 SEP 2005  
TRA L1 1- RN : 221 TERMS

FILE 'REGISTRY' ENTERED AT 08:54:54 ON 22 SEP 2005

L3 221 SEA ABB=ON PLU=ON L2

FILE 'WPIX' ENTERED AT 08:55:04 ON 22 SEP 2005

L4 1 SEA ABB=ON PLU=ON US2004162278/PN OR (US2003-693327# OR  
GB2002-24919# OR US2002-428632#)/AP,PRN

FILE 'REGISTRY' ENTERED AT 08:59:20 ON 22 SEP 2005

L5 82 SEA ABB=ON PLU=ON L3 AND N2CNC/ES

L6 STR

L7 6 SEA SSS SAM L6

L8 STR L6

L9 0 SEA CSS SAM L8

L10 75 SEA CSS FUL L8

SAV TEM L10 SHI327F0/A

L11 69 SEA ABB=ON PLU=ON L10 AND L3

FILE 'HCAPLUS' ENTERED AT 09:19:52 ON 22 SEP 2005

L12 4 SEA ABB=ON PLU=ON L10

FILE 'HCAOLD' ENTERED AT 09:20:44 ON 22 SEP 2005

L13 0 SEA ABB=ON PLU=ON L10

FILE 'USPATFULL, USPAT2' ENTERED AT 09:20:50 ON 22 SEP 2005

L14 5 SEA ABB=ON PLU=ON L10

FILE 'HCAPLUS' ENTERED AT 09:21:27 ON 22 SEP 2005

SEL AN 2 3 L12

L15 2 SEA ABB=ON PLU=ON ("140:391283"/AN OR "141:225517"/AN OR  
"2004:370921"/AN OR "2004:718543"/AN) AND L12

L16 2 SEA ABB=ON PLU=ON L12 NOT L15

FILE 'USPATFULL, USPAT2' ENTERED AT 09:23:06 ON 22 SEP 2005

SEL AN 1 3 4 L14

L17 3 SEA ABB=ON PLU=ON ("2004:209844"/AN OR "2004:240276"/AN OR  
"2005:31373"/AN) AND L14

L18 2 SEA ABB=ON PLU=ON L14 NOT L17

=> b reg

FILE 'REGISTRY' ENTERED AT 09:24:04 ON 22 SEP 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 21 SEP 2005 HIGHEST RN 863636-50-4

DICTIONARY FILE UPDATES: 21 SEP 2005 HIGHEST RN 863636-50-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005


Please note that search-term pricing does apply when conducting SmartSELECT searches.

```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

```
=> d que sta 110
L8 STR
```



```
REP G1=(0-1) C
REP G2=(0-1) 12
NODE ATTRIBUTES:
CONNECT IS M1 RC AT 6
CONNECT IS M1 RC AT 11
CONNECT IS M1 RC AT 12
DEFAULT MLEVEL IS ATOM
GGCAT IS SAT AT 8
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS M1 N AT 8
```

```
GRAPH ATTRIBUTES:
RSPEC 1
NUMBER OF NODES IS 12
```

```
STEREO ATTRIBUTES: NONE
L10 75 SEA FILE=REGISTRY CSS FUL L8
```

```
100.0% PROCESSED 351225 ITERATIONS 75 ANSWERS
SEARCH TIME: 00.00.09
```

```
=> b hcap
FILE 'HCAPLUS' ENTERED AT 09:24:10 ON 22 SEP 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available

Search done by Noble Jarrell



|               |                   |  |
|---------------|-------------------|--|
|               |                   | C07D498-04; C07D401-04; C07D413-14; C07D513-04;<br>C07D249-00; C07D243-00; C07D267-00  |
| WO 2004074291 | ECLA              | C07D401/04+213+211; C07D401/04+239B+211;<br>C07D413/14+271+213+211; C07D413/14+271+239B+211;<br>C07D487/04+249C+243C; C07D487/04+249C+245C;<br>C07D498/04+267C+249C; C07D498/04+273C+249C;<br>C07D513/04+281C+249C |
| US 2004186091 | NCL               | 514/210.210  |
|               | ECLA              | C07D401/04+213+211; C07D401/04+239B+211;<br>C07D413/14+271+213+211; C07D413/14+271+239B+211;<br>C07D487/04+249C+243C; C07D487/04+249C+245C;<br>C07D498/04+267C+249C; C07D498/04+273C+249C;<br>C07D513/04+281C+249C |
| NL 1025527    | ECLA              | C07D401/04+213+211; C07D401/04+239B+211;<br>C07D413/14+271+213+211; C07D413/14+271+239B+211;<br>C07D487/04+249C+243C; C07D487/04+249C+245C;<br>C07D498/04+267C+249C; C07D498/04+273C+249C;<br>C07D513/04+281C+249C |
| US 2005026810 | NCL               | 514/001.000  |
|               | ECLA              | C07D401/14R+249B+213+211   |
| OS            | MARPAT 141:225517 |  |
| GI            |                   |  |

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I [wherein V = -(CH<sub>2</sub>)<sub>d</sub>(O)e-, -CO-, -CH(alkyl)-; W = O, S(:O)a, NH and derivs.; X, Y = independently H, alkyl, halo, OH, CF<sub>3</sub>, OCF<sub>3</sub>, alkoxy, Z = -(CH<sub>2</sub>)<sub>f</sub>(O)g-, -CO-, -CH(alkyl)-; A = 4-7 membered (un)substituted saturated N-containing heterocycle; B = Ph, (un)substituted saturated N-containing heterocycle; a = 0-2; e, g = 0-1; d, f = 1-2; and their pharmaceutically acceptable derivs.] were prepared as vasopressin receptor V1a antagonists for the treatment of dysmenorrhea. Thus, amination of chloride II (preparation given) with 2-aminomethyl-4-chlorophenylamine (preparation given), cyclization of the aminooxadiazole, and reaction of amine with dimethylsulphamoyl chloride gave the triazole III. III displayed a K<sub>i</sub> = 0.24 nM in a V1a filter binding assay.

ST triazole prepn V1a antagonist dysmenorrhea

IT Blood vessel, disease  
(Raynaud's phenomenon, treatment; preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)

IT Vasopressin receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(V1a, antagonist; preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)

IT Heart, disease  
(angina pectoris, treatment; preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)

IT Antiarteriosclerotics  
(antiatherosclerotics; preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)

IT Uterus, disease  
(endometriosis, treatment; preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)

IT Heart, disease  
(failure, treatment; preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)

IT Embryo, animal, disease  
(fetus, intrauterine growth retardation, treatment; preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)

IT Sexual behavior  
(premature ejaculation, treatment; preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)

IT Parturition

- (premature, treatment; preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)
- IT Anti-inflammatory agents  
 Antianginal agents  
 Antiemetics  
 Antihypertensives  
 Antirheumatic agents  
 Anxiolytics  
 Cardiovascular agents  
 Diuretics  
 Human  
 (preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)
- IT Dysmenorrhea  
 (treatment of primary and secondary; preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)
- IT Anxiety  
 Atherosclerosis  
 Cardiovascular system, disease  
 Dysmenorrhea  
 Edema  
 Hypertension  
 Inflammation  
 Motion sickness  
 Preeclampsia  
 Rheumatoid arthritis  
 Vomiting  
 (treatment; preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)
- IT 748805-32-5P 748805-33-6P  
 RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (V1a receptor antagonist; preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)
- IT 748804-60-6P, 1-(3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748804-63-9P 748804-71-9P, 8-Chloro-1-[1-(pyrimidin-2-yl)piperidin-4-yl]-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748804-79-7P, 4-(8-Chloro-4H,6H-5-oxa-2,3,10b-triazabenz[e]azulen-1-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-6'-carbonitrile 748804-98-0P, 2-Chloro-1-[8-chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]ethanone 748805-02-9P 748805-09-6P, 8-Chloro-5-[(pyrrolidin-(2S)-2-yl)methyl]-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748805-13-2P 748805-14-3P, 5-(Azetidin-3-yl)-8-chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748805-15-4P, 8-Chloro-5-(pyrrolidin-3-yl)-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748805-20-1P 748805-66-5P, 8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-5-thia-2,3,10b-triazabenz[e]azulene 748806-39-5P, 8-Chloro-5-methyl-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (V1a receptor antagonist; preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)
- IT 748804-61-7P, 5-Methyl-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748804-62-8P, 1-[1-(3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]ethanone 748804-64-0P, 8-Chloro-5-methyl-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene trihydrochloride 748804-65-1P, 8-Chloro-5-isopropyl-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene trihydrochloride

748804-66-2P, 8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5-(tetrahydropyran-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene  
 748804-67-3P, 1-[8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]ethanone dihydrochloride  
 748804-68-4P, [8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]cyclopropylmethanone  
 dihydrochloride 748804-69-5P, 1-[8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]-2,2-dimethylpropan-1-one dihydrochloride 748804-70-8P, 8-Chloro-5-methanesulfonyl-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748804-72-0P, 8-Chloro-5-methyl-1-[1-(pyrimidin-2-yl)piperidin-4-yl]-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748804-73-1P, 8-Chloro-5-isopropyl-1-[1-(pyrimidin-2-yl)piperidin-4-yl]-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748804-74-2P, 8-Chloro-5-methanesulfonyl-1-[1-(pyrimidin-2-yl)piperidin-4-yl]-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748804-75-3P, [8-Chloro-1-[1-(pyrimidin-2-yl)piperidin-4-yl]-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]cyclopropylmethanone 748804-76-4P, 1-[8-Chloro-1-[1-(pyrimidin-2-yl)piperidin-4-yl]-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]-2,2-dimethylpropan-1-one 748804-77-5P, 1-[8-Chloro-1-[1-(pyrimidin-2-yl)piperidin-4-yl]-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]ethanone 748804-78-6P, 8-Chloro-1-(6'-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-5-oxa-2,3,10b-triazabenz[e]azulene 748804-80-0P, 4-(8-Chloro-4H,6H-5-oxa-2,3,10b-triazabenz[e]azulen-1-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-6'-carboxylic acid amide 748804-81-1P, 13-Chloro-3-(1,2,3,4,5,6-hexahydro-[1,2']bipyridinyl-4-yl)-2,4,5,8-tetraazatricyclo[9.4.0.02,6]pentadeca-1(11),3,5,12,14-pentaene 748804-82-2P, 1-[13-Chloro-3-(1,2,3,4,5,6-hexahydro-[1,2']bipyridinyl-4-yl)-2,4,5,8-tetraazatricyclo[9.4.0.02,6]pentadeca-1(11),3,5,12,14-pentaen-8-yl]ethanone 748804-83-3P, 13-Chloro-8-methyl-3-(1,2,3,4,5,6-hexahydro-[1,2']bipyridinyl-4-yl)-2,4,5,8-tetraazatricyclo[9.4.0.02,6]pentadeca-1(11),3,5,12,14-pentaene 748804-84-4P, 3-[1-(Pyrimidin-2-yl)piperidin-4-yl]-8-oxa-2,4,5-triazatricyclo[9.4.0.02,6]pentadeca-1(11),3,5,12,14-pentaene 748804-85-5P, 8-Chloro-1-[1-(pyrimidin-2-yl)piperidin-4-yl]-4H,6H-5-oxa-2,3,10b-triazabenz[e]azulene 748804-86-6P, 13-Chloro-3-(1,2,3,4,5,6-hexahydro-[1,2']bipyridinyl-4-yl)-8-oxa-2,4,5-triazatricyclo[9.4.0.02,6]pentadeca-1(11),3,5,12,14-pentaene 748804-87-7P, 3-(1,2,3,4,5,6-Hexahydro-[1,2']bipyridinyl-4-yl)-8-oxa-2,4,5-triazatricyclo[9.4.0.02,6]pentadeca-1(11),3,5,12,14-pentaene dihydrochloride 748804-88-8P, 8-Chloro-1-(1,2,3,4,5,6-hexahydro-[1,2']bipyridinyl-4-yl)-4H,6H-5-oxa-2,3,10b-triazabenz[e]azulene 748804-89-9P, 7-Chloro-1-(1,2,3,4,5,6-hexahydro-[1,2']bipyridinyl-4-yl)-4H,6H-5-oxa-2,3,10b-triazabenz[e]azulene dihydrochloride 748804-90-2P, 1-(1,2,3,4,5,6-Hexahydro-[1,2']bipyridinyl-4-yl)-4H,6H-5-oxa-2,3,10b-triazabenz[e]azulene 748804-91-3P, 8-Methoxy-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-5-oxa-2,3,10b-triazabenz[e]azulene dihydrochloride 748804-92-4P, 8-Fluoro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-5-oxa-2,3,10b-triazabenz[e]azulene 748804-93-5P, 8,9-Difluoro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-5-oxa-2,3,10b-triazabenz[e]azulene dihydrochloride 748804-94-6P, 9-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-5-oxa-2,3,10b-triazabenz[e]azulene dihydrochloride 748804-95-7P, 1-(3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-yl)-8-trifluoromethoxy-4H,6H-5-oxa-2,3,10b-triazabenz[e]azulene 748804-96-8P, 8-Methyl-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-5-oxa-2,3,10b-triazabenz[e]azulene 748804-99-1P, 2-(Azetidin-1-yl)-1-[8-chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]ethanone 748805-00-7P, 1-[8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]-2-(pyrrolidin-1-yl)ethanone 748805-01-8P, [8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]pyrrolidin-3-ylmethanone trihydrochloride 748805-03-0P 748805-04-1P 748805-05-2P 748805-06-3P 748805-07-4P 748805-08-5P 748805-10-9P 748805-11-0P 748805-12-1P 748805-16-5P, 8-Chloro-5-(piperidin-4-yl)-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-

yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene trihydrochloride  
 748805-17-6P, 8-Chloro-5-[1,4]oxazepan-6-yl-1-(3,4,5,6-tetrahydro-2H-  
 [1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene  
 trihydrochloride 748805-18-7P, [8-Chloro-1-(3,4,5,6-tetrahydro-2H-  
 [1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-  
 yl]morpholin-4-ylmethanone 748805-19-8P 748805-21-2P 748805-22-3P  
 748805-23-4P, [2-[8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-  
 yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]ethyl]dimethylamine  
 trihydrochloride 748805-24-5P, 8-Chloro-5-[2-(pyrrolidin-1-yl)ethyl]-1-  
 (3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-  
 tetraazabenz[e]azulene trihydrochloride 748805-25-6P,  
 [8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-  
 tetraazabenz[e]azulen-5-yl]acetic acid methyl ester 748805-26-7P,  
 1-[8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-  
 2,3,5,10b-tetraazabenz[e]azulen-5-yl]-3-methoxypropan-1-one  
 748805-27-8P 748805-28-9P, 8-Chloro-5-(1-methylpyrrolidin-2-yl)methanone  
 748805-35-8P 748805-36-9P 748805-37-0P 748805-38-1P 748805-39-2P  
 748805-40-5P 748805-41-6P, [8-Chloro-1-(3,4,5,6-tetrahydro-2H-  
 [1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-  
 yl](tetrahydropyran-4-yl)methanone 748805-42-7P, [8-Chloro-1-(3,4,5,6-  
 tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-  
 tetraazabenz[e]azulen-5-yl][1-(methyl)piperidin-4-yl]methanone  
 748805-43-8P, 8-Chloro-5-(1-methylazetidin-3-yl)-1-(3,4,5,6-tetrahydro-2H-  
 [1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene  
 748805-44-9P 748805-45-0P 748805-46-1P 748805-47-2P 748805-48-3P,  
 8-Chloro-5-(1-methylpyrrolidin-3-yl)-1-(3,4,5,6-tetrahydro-2H-  
 [1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene  
 748805-49-4P, 8-Chloro-5-(1-isopropylpyrrolidin-3-yl)-1-(3,4,5,6-  
 tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-  
 tetraazabenz[e]azulene trihydrochloride 748805-50-7P,  
 2-[8-Chloro-1-[1-(pyrimidin-2-yl)piperidin-4-yl]-4H,6H-2,3,5,10b-  
 tetraazabenz[e]azulen-5-yl]ethanol 748805-51-8P, 8-Chloro-5-(2-  
 methoxyethyl)-1-[1-(pyrimidin-2-yl)piperidin-4-yl]-5,6-dihydro-4H-  
 2,3,5,10b-tetraazabenz[e]azulene 748805-52-9P, 8-Chloro-5-(pyrimidin-2-  
 yl)-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-  
 2,3,5,10b-tetraazabenz[e]azulene 748805-53-0P, 8-Chloro-5-(pyrimidin-4-  
 yl)-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-  
 2,3,5,10b-tetraazabenz[e]azulene 748805-54-1P, 8-Chloro-1-(3,4,5,6-  
 tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-  
 tetraazabenz[e]azulene-5-carboxaldehyde 748805-55-2P,  
 8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-  
 tetraazabenz[e]azulene-5-sulfonic acid dimethylamide 748805-56-3P,  
 8-Chloro-5-[(pyridin-2-yl)methyl]-1-[1-(pyrimidin-2-yl)piperidin-4-yl]-5,6-  
 dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748805-57-4P 748805-58-5P  
 748805-59-6P, 8-Chloro-1-[1-(pyrimidin-2-yl)piperidin-4-yl]-4H,6H-  
 2,3,5,10b-tetraazabenz[e]azulene-5-sulfonic acid dimethylamide  
 748805-60-9P, 8-Chloro-5-methyl-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-  
 4-yl)-4,5-dihydro-2,3,5,10b-tetraazabenz[e]azulen-6-one 748805-61-0P,  
 13-Chloro-9-methyl-3-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-  
 2,4,5,9-tetraazatricyclo[9.4.0.0<sup>2,6</sup>]pentadeca-1(11),3,5,12,14-pentaene  
 748805-62-1P, 13-Chloro-8-methyl-3-[1-(pyrimidin-2-yl)piperidin-4-yl]-  
 2,4,5,8-tetraazatricyclo[9.4.0.0<sup>2,6</sup>]pentadeca-1(11),3,5,12,14-pentaene  
 748805-63-2P, 8-Chloro-5,6-dimethyl-1-[1-(pyrimidin-2-yl)piperidin-4-yl]-  
 5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748805-64-3P,  
 1-(3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-yl)-8-trifluoromethyl-4H,6H-5-  
 oxa-2,3,10b-triazabenz[e]azulene 748805-65-4P, 10-Chloro-1-(3,4,5,6-  
 tetrahydro-2H-[1,2']bipyridinyl-4-yl)-6,7-dihydro-4H-5,8-dioxa-2,3,12b-  
 triazabenz[a]cyclononene 748805-67-6P,  
 8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-5-thia-  
 2,3,10b-triazabenz[e]azulene 5-oxide 748805-68-7P, 8-Chloro-1-(3,4,5,6-  
 tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-5-thia-2,3,10b-

triazabenz[e]azulene 5,5-dioxide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(V1a receptor antagonist; preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)

IT 7440-23-5, Sodium, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study) (hypernatremia; preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)

IT 748804-97-9P, 1-[8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]-2-dimethylaminoethanone  
748806-17-9P 748806-18-0P 748806-19-1P 748806-20-4P 748806-21-5P  
748806-22-6P 748806-23-7P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(intermediate, V1a receptor antagonist; preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)

IT 19178-37-1P, 2-Amino-5-chloro-N-methylbenzamide 22908-49-2P, 2-(2-Methylaminoethyl)phenylamine 37585-16-3P, (2-Amino-4-chlorophenyl)methanol 39885-08-0P 55414-72-7P, (2-Amino-5-methoxyphenyl)methanol 65826-89-3P, 2-(2-Amino-5-chlorophenyl)ethanol 83265-56-9P, 2-Amino-5-trifluoromethoxybenzoic acid 108047-39-8P 154348-19-3P, 3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-carboxylic acid ethyl ester 215124-42-8P, (2-Amino-5-trifluoromethoxyphenyl)methanol 258850-08-7P, 7-Chloro-1,3,4,5-tetrahydrobenzo[e][1,4]diazepin-2-one 681464-03-9P, N-[2-(2-Acetylaminoethyl)phenyl]acetamide 685828-02-8P, 3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-carboxylic hydrazide 685828-03-9P, 1-(Pyrimidin-2-yl)piperidine-4-carboxylic hydrazide 685828-06-2P, N'-(2-Chloroacetyl)-3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-carboxylic hydrazide 685828-07-3P, N'-(2-Chloroacetyl)-1-(Pyrimidin-2-yl)piperidine-4-carboxylic hydrazide 685828-08-4P, 4-(5-Chloromethyl-[1,3,4]oxadiazol-2-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685828-09-5P, 2-[4-(5-Chloromethyl-[1,3,4]oxadiazol-2-yl)piperidin-1-yl]pyrimidine 685828-38-0P, 4-[[N'-(2-Chloroacetyl)hydrazino]carbonyl]piperidine-1-carboxylic acid tert-butyl ester 685828-39-1P, 4-(5-Chloromethyl-[1,3,4]oxadiazol-2-yl)piperidine-1-carboxylic acid tert-butyl ester 748805-69-8P, Acetic acid 2-(2-acetylamino-5-chlorophenyl)ethyl ester 748805-70-1P, [2-[[[5-(1,2,3,4,5,6-Hexahydro-[1,2']bipyridinyl-4-yl)[1,3,4]oxadiazol-2-yl]methyl]amino]methyl]phenyl]amine 748805-71-2P, [4-Chloro-2-[[[5-(1,2,3,4,5,6-hexahydro-[1,2']bipyridinyl-4-yl)[1,3,4]oxadiazol-2-yl]methyl]amino]methyl]phenyl]amine 748805-72-3P, [4-Chloro-2-[[[5-[1-(pyrimidin-2-yl)piperidin-4-yl][1,3,4]oxadiazol-2-yl]methyl]amino]methyl]phenyl]amine 748805-73-4P, [2-[[[5-(1,2,3,4,5,6-Hexahydro-[1,2']bipyridinyl-4-yl)-[1,3,4]oxadiazol-2-yl]methoxy]methyl]phenyl]amine 748805-74-5P, [3-Chloro-2-[[[5-(1,2,3,4,5,6-hexahydro-[1,2']bipyridinyl-4-yl)-[1,3,4]oxadiazol-2-yl]methoxy]methyl]phenyl]amine 748805-75-6P, [5-Chloro-2-[[[5-(1,2,3,4,5,6-hexahydro-[1,2']bipyridinyl-4-yl)-[1,3,4]oxadiazol-2-yl]methoxy]methyl]phenyl]amine 748805-76-7P, [4-Methoxy-2-[[[5-(1,2,3,4,5,6-hexahydro-[1,2']bipyridinyl-4-yl)-[1,3,4]oxadiazol-2-yl]methoxy]methyl]phenyl]amine 748805-77-8P, [4-Chloro-2-[[[5-(1,2,3,4,5,6-hexahydro-[1,2']bipyridinyl-4-yl)-[1,3,4]oxadiazol-2-yl]methoxy]methyl]phenyl]amine 748805-78-9P, [2-[2-[[5-(1,2,3,4,5,6-Hexahydro-[1,2']bipyridinyl-4-yl)-[1,3,4]oxadiazol-2-yl]methoxy]ethyl]phenyl]amine 748805-79-0P, [4-Chloro-2-[2-[[5-(1,2,3,4,5,6-hexahydro-[1,2']bipyridinyl-4-yl)-[1,3,4]oxadiazol-2-yl]methoxy]ethyl]phenyl]amine 748805-80-3P, [4-Chloro-2-[[[5-[1-(pyrimidin-2-yl)piperidin-4-yl]-[1,3,4]oxadiazol-2-yl]methoxy]methyl]phenyl]amine 748805-81-4P, [2-[2-[[5-[1-(Pyrimidin-2-yl)piperidin-4-yl]-[1,3,4]oxadiazol-2-yl]methoxy]ethyl]phenyl]amine 748805-82-5P, 4-[5-[(2-Amino-5-chlorobenzyloxy)methyl]-[1,3,4]oxadiazol-2-yl]piperidine-1-carboxylic acid tert-butyl ester 748805-83-6P, 4-(8-Chloro-4H,6H-5-oxa-2,3,10b-triazabenz[e]azulen-1-yl)piperidine-1-carboxylic acid tert-butyl ester 748805-84-7P, 8-Chloro-1-(piperidin-4-

yl)-4H,6H-5-oxa-2,3,10b-triazabenz[e]azulene 748805-85-8P,  
 (2-Amino-5-fluorophenyl)methanol 748805-86-9P, [4-Fluoro-2-[[[5-(1,2,3,4,5,6-hexahydro-[1,2']bipyridinyl-4-yl)-[1,3,4]oxadiazol-2-yl]methoxy]methyl]phenyl]amine 748805-87-0P, (2-Amino-4,5-difluorophenyl)methanol 748805-88-1P, [4,5-Difluoro-2-[[[5-(1,2,3,4,5,6-hexahydro-[1,2']bipyridinyl-4-yl)-[1,3,4]oxadiazol-2-yl]methoxy]methyl]phenyl]amine 748805-89-2P, [2-[[[5-(1,2,3,4,5,6-Hexahydro-[1,2']bipyridinyl-4-yl)-[1,3,4]oxadiazol-2-yl]methoxy]methyl]-4-trifluoromethoxyphenyl]amine 748805-90-5P, [4-Methyl-2-[[[5-(1,2,3,4,5,6-hexahydro-[1,2']bipyridinyl-4-yl)-[1,3,4]oxadiazol-2-yl]methoxy]methyl]phenyl]amine 748805-91-6P, N-[2-(2-Acetylaminoethyl)-4-chlorophenyl]acetamide 748805-92-7P, [2-(2-Aminoethyl)-4-chlorophenyl]amine dihydrochloride 748805-93-8P, [4-Chloro-2-[2-[[[5-(1,2,3,4,5,6-hexahydro-[1,2']bipyridinyl-4-yl)-[1,3,4]oxadiazol-2-yl]methyl]amino]ethyl]phenyl]amine 748805-94-9P 748805-95-0P 748805-96-1P, 6-Methylene-[1,4]oxazepane-4-carboxylic acid tert-butyl ester 748805-97-2P, 6-Oxo-[1,4]oxazepane-4-carboxylic acid tert-butyl ester 748805-98-3P, 2-(1-Methylaminoethyl)phenylamine 748805-99-4P, N-[2-[2-[(Acetyl)(methyl)amino]ethyl]phenyl]acetamide 748806-00-0P, N-[2-[1-[(Acetyl)methyl]amino]ethyl]phenyl]acetamide 748806-01-1P, N-[2-[2-[(Acetyl)(methyl)amino]ethyl]-4-chlorophenyl]acetamide 748806-02-2P, N-[2-[1-[(Acetyl)(methyl)amino]ethyl]-4-chlorophenyl]acetamide 748806-03-3P, [4-Chloro-2-(2-methylaminoethyl)phenyl]amine 748806-04-4P, 4-Chloro-2-[1-(methylamino)ethyl]phenylamine 748806-05-5P, 2-(5-Chloro-2-nitrophenoxy)ethanol 748806-06-6P, 3-[(5-Chloro-2-nitrobenzyl)amino]propionic acid methyl ester 748806-07-7P, 3-[(5-Chloro-2-nitrobenzyl)(methyl)amino]propionic acid methyl ester 748806-08-8P, 2-(2-Amino-5-chlorophenoxy)ethanol 748806-09-9P, 3-[(2-Amino-5-chlorobenzyl)(methyl)amino]propionic acid methyl ester 748806-10-2P, 3-[(2-Amino-5-chlorobenzyl)(methyl)amino]propionic acid dihydrochloride 748806-11-3P, Methyl[[5-(1,2,3,4,5,6-hexahydro-[1,2']bipyridinyl-4-yl)[1,3,4]oxadiazol-2-yl]methyl]amine 748806-12-4P, [4-Chloro-2-[2-[[[5-(1,2,3,4,5,6-hexahydro-[1,2']bipyridinyl-4-yl)-[1,3,4]oxadiazol-2-yl]methoxy]ethoxy]phenyl]amine 748806-13-5P, 2-Amino-5-chloro-N-methyl-N-[[[1,2,3,4,5,6-hexahydro-[1,2']bipyridinyl-4-yl)-[1,3,4]oxadiazol-2-yl]methyl]benzamide 748806-14-6P 748806-15-7P, [4-Chloro-2-[1-[[[4-(4-chlorophenyl)-5-[1-(pyrimidin-2-yl)piperidin-4-yl]-4H-[1,2,4]triazol-3-yl]methyl]methylamino]ethyl]phenyl]amine 748806-16-8P, tert-Butyl 3-[[8-Chloro-1-(1,2,3,4,5,6-hexahydro-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]carbonyl]pyrrolidine-1-carboxylate 748806-24-8P, 3-[8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]azetidine-1-carboxylic acid tert-butyl ester 748806-25-9P, 3-[8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]pyrrolidine-1-carboxylic acid tert-butyl ester 748806-26-0P, 4-[8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]piperidine-1-carboxylic acid tert-butyl ester 748806-27-1P, 6-[8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-10b-2,3,5,10b-tetraazabenz[e]azulen-5-yl]-[1,4]oxazepane-4-carboxylic acid 748806-28-2P, 8-Chloro-5-methyl-3,4,5,6-tetrahydro-1H-benzo[b][1,5]diazocin-2-one 748806-29-3P, 8-Chloro-5-methyl-3,4,5,6-tetrahydro-1H-benzo[b][1,5]diazocine-2-thione 748806-30-6P, 8-Chloro-5-methyl-2-methylsulfanyl-3,4,5,6-tetrahydrobenzo[b][1,5]diazocine 748806-31-7P, (2-Amino-5-chlorobenzylamino)acetic acid tert-butyl ester 748806-32-8P, 7-Chloro-4-methyl-1,3,4,5-tetrahydrobenzo[e][1,4]diazepin-2-one 748806-33-9P, 7-Chloro-4-methyl-1,3,4,5-tetrahydrobenzo[e][1,4]diazepine-2-thione 748806-34-0P, [(5-Chloro-2-nitrobenzyl)sulfanyl]acetic acid 748806-35-1P, 2-Chloro-5,9-dihydro-8-thia-5-azabenzocyclohepten-6-one 748806-36-2P, 2-Chloro-5,9-dihydro-8-thia-5-azabenzocycloheptene-6-thione 748806-37-3P, (2-Amino-5-chlorobenzyl)methylamine 748806-38-4P, (2-Amino-5-chlorobenzyl)(methyl)[[5-[1-(pyridin-2-yl)piperidin-4-yl]-1,3,4-oxadiazol-2-yl]methyl]amine 748806-40-8P, 8-Chloro-5-methyl-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-

tetraazabenz[e]azulene dibesylate

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)

- IT 89-77-0, 2-Amino-4-chlorobenzoic acid 96-32-2, Methyl bromoacetate 107-59-5 109-02-4, 4-Methylmorpholine 109-04-6, 2-Bromopyridine 123-75-1, Pyrrolidine, reactions 446-08-2, 2-Amino-5-fluorobenzoic acid 503-29-7, Azetidine 551-93-9, o-Aminoacetophenone 635-21-2, 5-Chloroanthranilic acid 700-37-8, 4-Chloro-2-fluoronitrobenzene 1118-68-9, N,N-Dimethylglycine 1121-60-4, 2-Pyridinecarboxaldehyde 1126-09-6, Ethyl isonipecotat 1722-12-9, 2-Chloropyrimidine 1871-57-4, 3-Chloro-2-chloromethyl-1-propene 2148-56-3, 2-Amino-6-chlorobenzoic acid 2544-06-1, 3-Methoxypropionic acid 3196-73-4,  $\beta$ -Alanine methyl ester hydrochloride 3282-30-2, 2,2-Dimethylpropionyl chloride 4023-34-1, Cyclopropanecarbonyl chloride 4403-69-4 4743-17-3, 5-Chloroisatoic anhydride 5337-03-1, Tetrahydro-4-pyranecarboxylic acid 5344-90-1, (2-Aminophenyl)methanol 5922-60-1, 2-Amino-5-chlorobenzonitrile 6269-99-4, N-[2-(2-Hydroxyethyl)phenyl]acetamide 6482-24-2, 2-Bromo-1-methoxyethane 6705-03-9, 2-Amino-5-methoxybenzoic acid 7568-92-5, 2-(2-Aminophenyl)ethanol 14788-12-6, 3-Dimethylaminopropionic acid hydrochloride 15159-40-7, Morpholinocarbonyl chloride 17180-93-7, 4-Chloropyrimidine 26690-80-2, (2-Hydroxyethyl)carbamic acid tert-butyl ester 29943-42-8, Tetrahydropyran-4-one 31577-25-0, 2-(Bromomethyl)-4-chloro-1-nitrobenzene 33100-16-2, N-Methyl-N-[2-(2-nitrophenyl)ethyl]amine 33252-29-8, 6-Chloropyridine-2-carbonitrile 34897-84-2, (2-Amino-5-methylphenyl)methanol 37585-25-4, (2-Amino-5-chlorophenyl)methanol 39890-95-4, 2-Chloro-6-trifluoromethylpyridine 48108-93-6, 2-(2-Aminoethyl)phenylamine 71985-80-3, 1-Methylpiperidine-4-carboxylic acid hydrochloride 79099-07-3, tert-Butyl 4-oxo-1-piperidinecarboxylate 83506-93-8, 2-Amino-4,5-difluorobenzoic acid 101385-93-7, tert-Butyl 3-oxo-1-pyrrolidinecarboxylate 111247-60-0, 1-(Pyrimidin-2-yl)piperidine-4-carboxylic acid ethyl ester 135072-32-1, 4-Phenylmethyl-2-morpholinecarboxylic acid ethyl ester 169037-23-4, 5-Trifluoromethoxy-1H-indole-2,3-dione 187834-88-4, 4-(Hydrazinocarbonyl)piperidine-1-carboxylic acid tert-butyl ester 212650-43-6, 4-(tert-Butoxycarbonyl)morpholine-3-carboxylic acid 220107-65-3 398489-26-4, 3-Oxoazetidine-1-carboxylic acid tert-butyl ester
- RL: RCT (Reactant); RACT (Reactant or reagent)
- (preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)
- IT 14127-61-8, Calcium (II) ion, biological studies
- RL: BSU (Biological study, unclassified); BIOL (Biological study)
- (release of intracellular; preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE


- (1) Albright, J; WO 9749707 A1 1997 HCAPLUS
- (2) American Home Prod; WO 9820011 A 1998 HCAPLUS
- (3) Ashwood, M; JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1: ORGANIC AND BIO-ORGANIC CHEMISTRY 1989, 11, HCAPLUS
- (4) Breslin, H; BIOORGANIC & MEDICINAL CHEMISTRY 1999, V7(11), P2427 HCAPLUS
- (5) Goel; SYNTHESIS 1987, 2, P162 HCAPLUS
- (6) Guaciaro, M; US 5438035 A 1995 HCAPLUS
- (7) Merck Sharp And Dohme Ltd; EP 0362942 A2 1990 HCAPLUS
- (8) Ortho McNeil Pharm Inc; WO 0043398 A 2000 HCAPLUS
- (9) Wyeth; WO 02083678 A 2002 HCAPLUS

IT 748806-15-7P, [4-Chloro-2-[1-[[[4-(4-chlorophenyl)-5-[1-(pyrimidin-2-yl)piperidin-4-yl]-4H-[1,2,4]triazol-3-yl]methyl]methylamino]ethyl]phenyl]amine

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)

RN 748806-15-7 HCAPLUS  
 CN 4H-1,2,4-Triazole-3-methanamine, N-[1-(2-amino-5-chlorophenyl)ethyl]-4-(4-chlorophenyl)-N-methyl-5-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



✓ L15 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2004:370921 HCAPLUS  
 DN 140:391283  
 ED Entered STN: 07 May 2004  
 TI Preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea  
 IN Armour, Robert Duncan; Baxter, Andrew Douglas; Bryans, Justin Stephen; Dack, Kevin Neil; Johnson, Patrick Stephen; Lewthwaite, Russell Andrew; Newman, Julie; Rawson, David James; Ryckmans, Thomas  
 PA Pfizer Limited, UK; Pfizer Inc.  
 SO PCT Int. Appl., 122 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM C07D401-04  
 ICS C07D401-06; C07D401-14; C07D413-04; C07D413-06; C07D413-14; A61K031-4196; A61P009-00; A61P007-00; A61P013-00; A61P025-00; C07D403-12; C07D401-12; C07D405-14  
 CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))  
 Section cross-reference(s): 1, 63

FAN.CNT 1

| PATENT NO.  | KIND | DATE     | APPLICATION NO. | DATE     |
|---|------|----------|-----------------|----------|
| WO 2004037809   | A1   | 20040506 | WO 2003-IB4587  | 20031014 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW |      |          |                 |          |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  |      |          |                 |          |
| CA 2502932  | AA   | 20040506 | CA 2003-2502932 | 20031014 |
| EP 1558598  | A1   | 20050803 | EP 2003-748487  | 20031014 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK   |      |          |                 |          |
| US 2004162278   | A1   | 20040819 | US 2003-693327  | 20031024 |
| PRAI GB 2002-24919  | A    | 20021025 |                 |          |
| US 2002-428632P   | P    | 20021122 |                 |          |
| WO 2003-IB4587  | W    | 20031014 |                 |          |

CLASS

PATENT NO. CLASS PATENT FAMILY CLASSIFICATION CODES



|               |                   |   |
|---------------|-------------------|---|
| WO 2004037809 | ICM<br>ICS        | C07D401-04<br>C07D401-06; C07D401-14; C07D413-04; C07D413-06;<br>C07D413-14; A61K031-4196; A61P009-00; A61P007-00;<br>A61P013-00; A61P025-00; C07D403-12; C07D401-12;<br>C07D405-14   |
| WO 2004037809 | ECLA              | C07D401/04+249B+211; C07D401/06+249B+211;<br>C07D401/12+249B+213; C07D401/14+249B+213+211;<br>C07D401/14+249B+239B+211; C07D401/14+249B+241B+211;<br>C07D401/14+249B+213+211+211;<br>C07D401/14+249B+213+211+207;<br>C07D401/14+249B+239B+211+211;<br>C07D401/14+249B+249+213+211;<br>C07D401/14+249B+213+213+211; C07D403/12+249B+239B;<br>C07D405/14+307B+249B+213+211;<br>C07D405/14+309+249B+213+211; C07D413/04+271+211;<br>C07D413/06+271+211; C07D413/14+271+213+211;<br>C07D413/14+271+213+211+211; C07D413/14+271+239B+211             |
| CA 2502932    | ECLA              | C07D401/04+249B+211; C07D401/06+249B+211;<br>C07D401/12+249B+213; C07D401/14+249B+213+211;<br>C07D401/14+249B+213+211+207;<br>C07D401/14+249B+213+211+211;<br>C07D401/14+249B+213+213+211; C07D401/14+249B+239B+211;<br>C07D401/14+249B+239B+211+211; C07D401/14+249B+241B+211;<br>C07D401/14+249B+249+213+211; C07D403/12+249B+239B;<br>C07D405/14+307B+249B+213+211;<br>C07D405/14+309+249B+213+211; C07D413/04+271+211;<br>C07D413/06+271+211; C07D413/14+271+213+211;<br>C07D413/14+271+213+211+211; C07D413/14+271+239B+211                |
| EP 1558598    | ECLA              | C07D401/04+249B+211; C07D401/06+249B+211;<br>C07D401/12+249B+213; C07D401/14+249B+213+211;<br>C07D401/14+249B+213+211+207;<br>C07D401/14+249B+213+211+211;<br>C07D401/14+249B+213+213+211; C07D401/14+249B+239B+211;<br>C07D401/14+249B+239B+211+211; C07D401/14+249B+241B+211;<br>C07D401/14+249B+249+213+211; C07D403/12+249B+239B;<br>C07D405/14+307B+249B+213+211;<br>C07D405/14+309+249B+213+211; C07D413/04+271+211;<br>C07D413/06+271+211; C07D413/14+271+213+211;<br>C07D413/14+271+213+211+211; C07D413/14+271+239B+211                |
| US 2004162278 | NCL<br>ECLA       | 514/210.200<br>C07D401/04+249B+211; C07D401/06+249B+211;<br>C07D401/12+249B+213; C07D401/14+249B+213+211;<br>C07D401/14+249B+213+211+207;<br>C07D401/14+249B+213+211+211;<br>C07D401/14+249B+213+213+211; C07D401/14+249B+239B+211;<br>C07D401/14+249B+239B+211+211; C07D401/14+249B+241B+211;<br>C07D401/14+249B+249+213+211; C07D403/12+249B+239B;<br>C07D405/14+307B+249B+213+211;<br>C07D405/14+309+249B+213+211; C07D413/04+271+211;<br>C07D413/06+271+211; C07D413/14+271+213+211;<br>C07D413/14+271+213+211+211; C07D413/14+271+239B+211 |
| OS<br>GI      | MARPAT 140:391283 |   |

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I [wherein R1 = cyclo/alkyl, (CH<sub>2</sub>)cW, (CH<sub>2</sub>)cZ(CH<sub>2</sub>)dW; W = alkyl, alkyloxy, CONH<sub>2</sub> and derivs., NH<sub>2</sub> and derivs., (un)substituted Ph, etc.; Z = O or S(O)g; g = 0-2; R2 = Ph optionally fused to a 5- or 6-membered aryl or heteroaryl; Y = (CHR<sub>3</sub>)a; R3 = independently H, alkyl, OH and derivs., etc.; X = (CH<sub>2</sub>)b; a, b = independently 0-1; c, d = 0-4; A = 4-, 5- or 6-membered saturated heterocyclyl, B = (un)substituted Ph, 4-, 5-, or 6-membered (un)saturated heterocyclyl; their pharmaceutically acceptable

salts and solvates] were prepared as vasopressin receptor V1a antagonists for the treatment of dysmenorrhea. Thus, reacting oxadiazole II (preparation given) with (S)-1-phenylethylamine in the presence of anhydrous MgCl<sub>2</sub> at 150° gave triazole III. I showed K<sub>i</sub> values < 500 nM in a V1a filter binding assay.

- ST triazole prepn V1a antagonist dysmenorrhea
- IT Blood vessel, disease
  - (Raynaud's phenomenon, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
- IT Vasopressin receptors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study)
  - (V1a, antagonist; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
- IT Behavior
  - (aggressive; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
- IT Appetite
  - (anorexia nervosa, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
- IT Antiarteriosclerotics
  - (antiatherosclerotics; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
- IT Ischemia
  - (cardiac, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
- IT Nervous system, disease
  - (central; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
- IT Mental disorder
  - (cognitive, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
- IT Mental disorder
  - (depression, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
- IT Urogenital tract
  - (disease, infection, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
- IT Sexual behavior
  - (disorder, treatment of male and female; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
- IT Cognition
  - (disorder, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
- IT Uterus, disease
  - (endometriosis, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
- IT Heart, disease
- Kidney, disease
  - (failure, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
- IT Reproductive tract, disease
  - (female, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
- IT Embryo, animal, disease
  - (fetus, intrauterine growth retardation, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
- IT Spinal cord, disease
  - (injury, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
- IT Heart, disease
  - (ischemia, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
- IT Diabetes mellitus
  - (non-insulin-dependent, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
- IT Mental disorder

- (obsession-compulsion, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
- IT Contraceptives
  - Drug delivery systems
    - (oral; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
- IT Sexual behavior
  - (premature ejaculation, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
- IT Parturition
  - (premature, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
- IT Anti-Alzheimer's agents
  - Anti-ischemic agents
  - Antiasthmatics
  - Antidepressants
  - Antidiabetic agents
  - Antiemetics
  - Antiglaucoma agents
  - Antihypertensives
  - Antiobesity agents
  - Antitumor agents
  - Anxiolytics
  - Cardiovascular agents
  - Cognition enhancers
  - Diuretics
  - Human
  - Hypnotics and Sedatives
  - Thrombolytics
    - (preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
- IT Injury
  - (spinal cord, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
- IT Ischemia
  - (treatment of cerebrovascular; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
- IT Alzheimer's disease
  - Anxiety
  - Asthma
  - Atherosclerosis
  - Calculi, urinary
  - Cardiovascular system, disease
  - Cataract
  - Cirrhosis
  - Cushing's syndrome
  - Diabetes mellitus
  - Digestive tract, disease
  - Dysmenorrhea
  - Edema
  - Glaucoma (disease)
  - Heart, disease
  - Hypertension
  - Ischemia
  - Kidney
  - Kidney, disease
  - Lung, disease
  - Lung, neoplasm
  - Micturition
  - Motion sickness
  - Neoplasm
  - Nervous system agents
  - Obesity
  - Sleep disorders
  - Thrombosis
  - Vomiting

- (treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
- IT Infection  
(urogenital, treatment; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
- IT 685827-43-4P, 4-[4-Benzyl-5-[4-(methanesulfonyl)piperazin-1-ylmethyl]-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl  
685827-47-8P, 4-[4-Benzyl-5-[(morpholin-4-yl)methyl]-4H-[1,2,4]triazol-3-yl]-3'-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(V1a receptor antagonist, V1a receptor antagonist; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
- IT 685827-36-5P, 4-[4-(3-Chlorobenzyl)-5-methyl-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-69-4P,  
4-[4-Benzyl-5-(2-oxa-5-azabicyclo[2.2.1]hept-5-ylmethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(V1a receptor antagonist; preparation of triazoles as V1a receptor antagonists for treatment of dysmenorrhea)
- IT 685827-26-3P, Benzyl 4-[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl]piperazine-1-carboxylate  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(V1a receptor antagonist, intermediate; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)
- IT 685826-99-7P, (S)-4-[5-Butyl-4-(1-phenylethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-00-3P,  
2-[4-(4-Benzyl-5-isobutyl-4H-[1,2,4]triazol-3-yl)piperidin-1-yl]pyrimidine  
685827-01-4P, (S)-4-[5-Methyl-4-(1-phenylethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-02-5P,  
4-(4-Benzyl-5-butyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-03-6P, 2-[4-(4-Benzyl-5-isopropyl-4H-[1,2,4]triazol-3-yl)piperidin-1-yl]pyrimidine 685827-04-7P,  
2-[4-(4-Benzyl-5-cyclopropyl-4H-[1,2,4]triazol-3-yl)piperidin-1-yl]pyrimidine 685827-05-8P, (S)-2-[4-[5-Methyl-4-(1-phenylpropyl)-4H-[1,2,4]triazol-3-yl]piperidin-1-yl]pyrimidine  
685827-06-9P, 2-[4-(4-Benzyl-5-propyl-4H-[1,2,4]triazol-3-yl)piperidin-1-yl]pyrimidine 685827-07-0P, 2-[4-[4-Benzyl-5-(2-chlorophenoxy)methyl]-4H-[1,2,4]triazol-3-yl]piperidin-1-yl]pyrimidine  
685827-08-1P, 2-[4-(4-Benzyl-5-butyl-4H-[1,2,4]triazol-3-yl)piperidin-1-yl]pyrimidine 685827-09-2P, (S)-2-[4-[5-Methyl-4-(1-phenylethyl)-4H-[1,2,4]triazol-3-yl]piperidin-1-yl]pyrimidine  
685827-10-5P, 2-[4-[4-Benzyl-5-(4-fluorophenoxy)methyl]-4H-[1,2,4]triazol-3-yl]piperidin-1-yl]pyrimidine 685827-11-6P,  
2-[4-[5-Methyl-4-(3-methylbenzyl)-4H-[1,2,4]triazol-3-yl]piperidin-1-yl]pyrimidine 685827-12-7P, (S)-2-[4-[5-Methyl-4-(1-phenylethyl)-4H-[1,2,4]triazol-3-ylmethyl]piperidin-1-yl]pyrimidine  
685827-13-8P, 2-[4-[4-(3-Fluorobenzyl)-5-methyl-4H-[1,2,4]triazol-3-yl]piperidin-1-yl]pyrimidine 685827-14-9P,  
4-(4-Benzyl-5-[(morpholin-4-yl)methyl]-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-15-0P,  
4-[4-Benzyl-5-[(benzyloxy)methyl]-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-16-1P,  
4-(4-Benzyl-5-methyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-17-2P, (R)-2-[3-Methyl-5-[1-(pyrimidin-2-yl)piperidin-4-yl]-[1,2,4]triazol-4-yl]-2-phenylethanol 685827-18-3P,  
2-[4-(4-Benzyl-5-methyl-4H-[1,2,4]triazol-3-yl)piperidin-1-yl]-4-methylpyrimidine 685827-19-4P, 2-[4-(4-Benzyl-5-methyl-4H-[1,2,4]triazol-3-yl)piperidin-1-yl]pyrimidine 685827-20-7P,  
4-(4-Benzyl-5-methyl-4H-[1,2,4]triazol-3-yl)-1-phenylpiperidine

685827-21-8P, 2-[4-(4-Benzyl-5-methyl-4H-[1,2,4]triazol-3-yl)piperidin-1-yl]pyrazine 685827-22-9P,  
 4-(4-Benzyl-5-[(piperidin-1-yl)methyl]-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-23-0P,  
 (S)-4-[4-(1-Phenylethyl)-5-[(piperidin-1-yl)methyl]-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-24-1P,  
 4-[4-Benzyl-5-(4-methoxypiperidin-1-ylmethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-25-2P,  
 (S)-4-[5-(4-Methoxypiperidin-1-ylmethyl)-4-(1-phenylethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl  
 685827-27-4P, 4-[4-Benzyl-5-[[2-(morpholin-4-yl)ethoxy]methyl]-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl  
 685827-28-5P, 4-[4-Benzyl-5-((3R)-3-methoxypyrrolidin-1-ylmethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl  
 685827-29-6P 685827-30-9P 685827-31-0P  
 685827-32-1P 685827-33-2P 685827-34-3P  
 685827-35-4P 685827-37-6P, N-Benzyl-2-[4-benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-yl]acetamide 685827-38-7P, 2-[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethoxy]ethylamine  
 685827-39-8P, N-[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl]ethylamine  
 685827-40-1P, [4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl](2-methoxyethyl)amine  
 685827-41-2P, [4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl](3-methoxypropyl)amine  
 685827-42-3P, 1-[4-[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl]piperazin-1-yl]ethanone 685827-44-5P, N-[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl]methanesulfonamide  
 685827-45-6P, [4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl](2-methoxyethyl)methylamine  
 685827-46-7P, [4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl](3-methoxypropyl)methylamine  
 685827-48-9P, 4-(4-Benzyl-5-[(morpholin-4-yl)methyl]-4H-[1,2,4]triazol-3-yl)-3'-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl  
 685827-49-0P, 4-(4-Benzyl-5-[(morpholin-4-yl)methyl]-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-3'-carbonitrile  
 685827-50-3P, 4-(4-Benzyl-5-[(morpholin-4-yl)methyl]-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-3'-carboxylic acid amide  
 685827-51-4P, (S)-4-[[4-(1-Phenylethyl)-5-[4-(pyridin-2-yl)piperazin-1-ylmethyl]-4H-[1,2,4]triazol-3-yl]methyl]morpholine trihydrochloride 685827-52-5P, (S)-4-[[4-(1-Phenylethyl)-5-[[4-(pyrimidin-2-yl)piperazin-1-yl]methyl]-4H-[1,2,4]triazol-3-yl]methyl]morpholine trihydrochloride 685827-53-6P,  
 1-[[4-Benzyl-5-[1-(pyrimidin-2-yl)piperidin-4-yl]-4H-[1,2,4]triazol-3-yl]methyl]piperidin-3-ol 685827-54-7P, (R)-2-[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-yl]pyrrolidine-1-carboxylic acid tert-butyl ester 685827-55-8P,  
 (R)-4-[4-Benzyl-5-[(tetrahydrofuran-3-yl)oxy]methyl]-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-56-9P,  
 (S)-4-[4-Benzyl-5-[(tetrahydrofuran-3-yl)oxy]methyl]-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-57-0P,  
 [[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl]methylamino]acetic acid tert-butyl ester  
 685827-58-1P, 4-[4-Benzyl-5-(tetrahydropyran-4-ylmethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl  
 685827-59-2P, 4-[4-Benzyl-5-(tetrahydrofuran-2-yl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-60-5P,  
 4-[4-Benzyl-5-(ethoxymethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-61-6P, 4-[4-Benzyl-5-(2-methoxyethoxymethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-62-7P, [4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethoxy]acetic acid tert-butyl ester 685827-63-8P, N-Benzyl-2-[4-benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-

ylmethoxy]acetamide 685827-64-9P, 4-[4-Benzyl-5-  
[(methylsulfanyl)methyl]-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-  
[1,2']bipyridinyl 685827-65-0P, 4-(4-Benzyl-5-[(pyrazol-1-  
yl)methyl]-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl  
685827-66-1P, 4-(4-Benzyl-5-[(1,2,3]triazol-2-yl)methyl]-4H-  
[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl  
685827-67-2P, 4-(4-Benzyl-5-[1,2,3]triazol-1-ylmethyl-4H-[1,2,4]triazol-3-  
yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-68-3P,  
4-[4-Benzyl-5-(pyridin-4-yloxy)methyl]-4H-[1,2,4]triazol-3-yl]-3,4,5,6-  
tetrahydro-2H-[1,2']bipyridinyl  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(V1a receptor antagonist; preparation of triazoles as V1a receptor  
antagonists for the treatment of dysmenorrhea)

IT 7440-23-5, Sodium, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(hyponatremia; preparation of triazoles as V1a receptor antagonists for the  
treatment of dysmenorrhea)

IT 474707-30-7P, (3R)-3-Methoxypyrrolidine hydrochloride 549532-08-3P,  
(3R)-3-Methoxypyrrolidine-1-carboxylic acid tert-butyl ester  
550371-69-2P, (3S)-3-Methoxypyrrolidine-1-carboxylic acid tert-butyl ester  
685827-70-7P, 3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-carboxylic acid  
685827-71-8P, N'-Butyryl-1-(Pyrimidin-2-yl)piperidine-4-carboxylic  
hydrazide 685827-72-9P 685827-73-0P 685827-74-1P 685827-75-2P  
685827-76-3P 685827-77-4P 685827-78-5P 685827-79-6P 685827-80-9P,  
N'-Pentanoyl-3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-carboxylic  
hydrazide 685827-81-0P, N'-Acetyl-3,4,5,6-Tetrahydro-2H-  
[1,2']bipyridinyl-4-carboxylic hydrazide 685827-82-1P,  
N'-[2-(Morpholin-4-yl)acetyl]-3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-  
carboxylic hydrazide 685827-83-2P, 1-(Pyrimidin-2-yl)piperidine-4-  
carboxylic hydrazide monohydrochloride 685827-84-3P,  
N'-(3-Methylbutyryl)-1-(pyrimidin-2-yl)piperidine-4-carboxylic hydrazide  
685827-86-5P, 2-[4-(5-Isobutyl-[1,3,4]oxadiazol-2-yl)piperidin-1-  
yl]pyrimidine 685827-87-6P 685827-88-7P 685827-89-8P 685827-90-1P  
685827-91-2P 685827-92-3P 685827-93-4P 685827-94-5P 685827-95-6P  
685827-96-7P 685827-97-8P, 2-[4-(5-Methyl-[1,3,4]oxadiazol-2-  
yl)piperidin-1-yl]pyrimidine 685827-98-9P, 4-(4-Benzyl-5-methyl-4H-  
[1,2,4]triazol-3-yl)piperidine-1-carboxylic acid tert-butyl ester  
685827-99-0P, 4-(4-Benzyl-5-methyl-4H-[1,2,4]triazol-3-yl)piperidine  
monohydrochloride 685828-00-6P, 4-[(5-Methyl-[1,3,4]oxadiazol-2-  
yl)methyl]piperidine monohydrochloride 685828-01-7P,  
2-[4-[(5-Methyl-[1,3,4]oxadiazol-2-yl)methyl]piperidin-1-yl]pyrimidine  
685828-02-8P, 3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-carboxylic  
hydrazide 685828-03-9P, 1-(Pyrimidin-2-yl)piperidine-4-carboxylic  
hydrazide 685828-04-0P, N'-(2-Benzoyloxyacetyl)-3,4,5,6-Tetrahydro-2H-  
[1,2']bipyridinyl-4-carboxylic hydrazide 685828-05-1P,  
4-[5-[(Benzoyloxy)methyl]-[1,3,4]oxadiazol-2-yl]-3,4,5,6-tetrahydro-2H-  
[1,2']bipyridinyl 685828-06-2P, N'-(2-Chloroacetyl)-3,4,5,6-Tetrahydro-  
2H-[1,2']bipyridinyl-4-carboxylic hydrazide 685828-07-3P,  
N'-(2-Chloroacetyl)-1-(pyrimidin-2-yl)piperidine-4-carboxylic hydrazide  
685828-08-4P, 4-(5-Chloromethyl-[1,3,4]oxadiazol-2-yl)-3,4,5,6-tetrahydro-  
2H-[1,2']bipyridinyl 685828-09-5P, 2-[4-(5-Chloromethyl-[1,3,4]oxadiazol-  
2-yl)piperidin-1-yl]pyrimidine 685828-10-8P, 4-[5-[(Piperidin-1-  
yl)methyl]-[1,3,4]oxadiazol-2-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl  
685828-11-9P 685828-12-0P 685828-13-1P, 4-[5-[[2-(Morpholin-4-  
yl)ethoxy]methyl]-[1,3,4]oxadiazol-2-yl]-3,4,5,6-tetrahydro-2H-  
[1,2']bipyridinyl 685828-14-2P, 3-Oxo-3-[2-[(3,4,5,6-tetrahydro-2H-  
[1,2']bipyridin-4-yl)carbonyl]hydrazino]propionic acid tert-butyl ester  
685828-15-3P, [5-(3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-  
yl)[1,3,4]oxadiazol-2-yl]acetic acid tert-butyl ester 685828-16-4P,  
(3S)-3-Methoxypyrrolidine hydrochloride 685828-17-5P 685828-18-6P  
685828-19-7P 685828-20-0P 685828-21-1P 685828-22-2P 685828-23-3P  
685828-24-4P 685828-25-5P, Ethyl-[5-(3,4,5,6-Tetrahydro-2H-  
[1,2']bipyridinyl-4-yl)-[1,3,4]oxadiazol-2-ylmethyl]amine 685828-26-6P,  
[2-[5-(3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-yl)-[1,3,4]oxadiazol-2-

ylmethoxy]ethyl]carbamic acid tert-butyl ester 685828-27-7P,  
 [5-(3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-yl)-[1,3,4]oxadiazol-2-ylmethyl]carbamic acid tert-butyl ester 685828-28-8P 685828-29-9P  
 685828-30-2P 685828-31-3P, [4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl]carbamic acid tert-butyl ester 685828-32-4P 685828-33-5P  
 685828-34-6P 685828-35-7P, [2-[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethoxy]ethyl]carbamic acid tert-butyl ester 685828-36-8P  
 685828-37-9P, 4-(4-Benzyl-5-[(piperazin-1-yl)methyl]-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685828-38-0P 685828-39-1P, 4-(5-Chloromethyl-[1,3,4]oxadiazol-2-yl)piperidine-1-carboxylic acid tert-butyl ester 685828-40-4P, 4-[5-[(Morpholin-4-yl)methyl]-[1,3,4]oxadiazol-2-yl]piperidine-1-carboxylic acid tert-butyl ester 685828-41-5P, 4-(4-Benzyl-5-morpholin-4-ylmethyl-4H-[1,2,4]triazol-3-yl)piperidine-1-carboxylic acid tert-butyl ester 685828-42-6P, 4-[[4-Benzyl-5-(piperidin-4-yl)-4H-[1,2,4]triazol-3-yl)methyl]morpholine 685828-43-7P 685828-44-8P, 4-[(5-Chloromethyl-[1,3,4]oxadiazol-2-yl)methyl]morpholine 685828-45-9P, 4-[[5-[4-(Pyridin-2-yl)piperazin-1-ylmethyl]-[1,3,4]oxadiazol-2-yl)methyl]morpholine 685828-46-0P, 4-[[5-[4-(Pyrimidin-2-yl)piperazin-1-ylmethyl]-[1,3,4]oxadiazol-2-yl)methyl]morpholine 685828-47-1P, 1-[[5-[1-(Pyrimidin-2-yl)piperidin-4-yl]-[1,3,4]oxadiazol-2-yl)methyl]piperidin-3-ol 685828-48-2P, (R)-2-[N'-[(3,4,5,6-Tetrahydro-2H-[1,2']bipyridin-4-yl)carbonyl]hydrazinocarbonyl]pyrrolidine-1-carboxylic acid tert-butyl ester 685828-50-6P, (R)-2-[5-(3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-yl)-[1,3,4]oxadiazol-2-yl]pyrrolidine-1-carboxylic acid tert-butyl ester 685828-51-7P, (R)-4-[5-[(Tetrahydrofuran-3-yl)oxy]methyl]-[1,3,4]oxadiazol-2-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685828-52-8P, (S)-4-[5-[(Tetrahydrofuran-3-yl)oxy]methyl]-[1,3,4]oxadiazol-2-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685828-53-9P, [Methyl[5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)[1,3,4]oxadiazol-2-ylmethyl]amino]acetic acid tert-butyl ester 685828-54-0P, N'-[(3,4,5,6-Tetrahydro-2H-[1,2']bipyridin-4-yl)carbonyl]tetrahydrofuran-2-carboxylic hydrazide 685828-55-1P, 4-[5-(Tetrahydrofuran-2-yl)-[1,3,4]oxadiazol-2-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685828-56-2P, 3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-carboxylic acid N'-(2-tetrahydropyran-4-ylacetyl)hydrazide 685828-57-3P, 4-[5-(Tetrahydropyran-4-ylmethyl)-[1,3,4]oxadiazol-2-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685828-58-4P, 4-(5-Ethoxymethyl-[1,3,4]oxadiazol-2-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685828-59-5P, 4-[5-(2-Methoxyethoxymethyl)-[1,3,4]oxadiazol-2-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685828-60-8P, [5-(3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-yl)[1,3,4]oxadiazol-2-ylmethoxy]acetic acid tert-butyl ester 685828-62-0P, 4-[5-[(Pyrazol-1-yl)methyl]-[1,3,4]oxadiazol-2-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685828-63-1P 685828-64-2P, 4-[5-[[[1,2,3]Triazol-1-yl)methyl]-[1,3,4]oxadiazol-2-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685828-65-3P, 4-[5-(Pyridin-4-yloxy)methyl]-[1,3,4]oxadiazol-2-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of triazoles as V1a receptor antagonists for treatment of dysmenorrhea)

IT 79-30-1, Isobutyryl chloride 98-91-9, Benzenecarbothioic acid 108-12-3, 3-Methylbutyryl chloride 108-86-1, Bromobenzene, reactions 109-02-4, 4-Methylmorpholine 109-09-1, 2-Chloropyridine 109-85-3 110-91-8, Morpholine, reactions 123-75-1, Pyrrolidine, reactions 288-13-1, 1H-Pyrazole 288-35-7, 2H-[1,2,3]Triazole 541-16-2, tert-Butyl malonate 622-40-2, 2-(Morpholin-4-yl)ethanol 626-64-2, 4-Hydroxypyridine 770-17-2 870-46-2, Hydrazinecarboxylic acid tert-butyl ester 1722-12-9, 2-Chloropyrimidine 2627-86-3, ((S)-(-)-1-Phenylethyl)amine 3430-17-9, 2-Bromo-3-methylpyridine 3538-65-6, Butyric acid hydrazide 4595-60-2, 2-Bromopyrimidine 5332-73-0 5616-81-9 6602-54-6, 2-Chloro-3-cyanopyridine 6859-99-0,

Piperidin-3-ol 14508-49-7, 2-Chloropyrazine 16874-33-2,  
 Tetrahydrofuran-2-carboxylic acid 19810-31-2 26690-80-2, tert-Butyl  
 N-(2-hydroxyethyl)carbamate 38291-82-6, Pentanoic acid hydrazide  
 40499-83-0, 3-Hydroxypyrrolidine 50595-15-8 51957-36-9,  
 1-(2-Pyrimidyl)piperidine 56613-80-0, (R)-(-)-2-Amino-2-phenylethanol  
 57260-71-6 65753-47-1, 2-Chloro-3-trifluoromethylpyridine 68654-52-4,  
 1-(2-Pyridyl)piperidine 86087-23-2, (S)-Tetrahydrofuran-3-ol  
 86087-24-3, (R)-Tetrahydrofuran-3-ol 101469-92-5, (3S)-3-  
 Hydroxypyrrolidine-1-carboxylic acid tert-butyl ester 109431-87-0,  
 (3R)-3-Hydroxypyrrolidine-1-carboxylic acid tert-butyl ester  
 111247-60-0, 1-(Pyrimidin-2-yl)piperidine-4-carboxylic acid ethyl ester  
 120099-60-7 120099-61-8 130645-48-6, 2-Bromo-4-methylpyrimidine  
 154348-19-3, 3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-carboxylic acid  
 ethyl ester 187834-88-4, 4-(Hydrazinocarbonyl)piperidine-1-carboxylic  
 acid tert-butyl ester 280110-69-2, 4-(5-Methyl-[1,3,4]oxadiazol-2-  
 yl)piperidine-1-carboxylic acid tert-butyl ester 303144-44-7,  
 1-(Pyrimidin-2-yl)piperidine-4-carboxylic acid 547716-11-0 685827-85-4  
 685828-49-3 685828-61-9, 4-[5-[(Methylsulfonyl)methyl]-[1,3,4]oxadiazol-  
 2-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl  
 RL: RCT (Reactant); RACT (Reactant or reagent)


(preparation of triazoles as V1a receptor antagonists for treatment of  
 dysmenorrhea)

IT 685827-43-4P, 4-[4-Benzyl-5-[4-(methanesulfonyl)piperazin-1-  
 ylmethyl]-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(V1a receptor antagonist, V1a receptor antagonist; preparation of triazoles  
 as V1a receptor antagonists for the treatment of dysmenorrhea)

RN 685827-43-4 HCAPLUS

CN Piperazine, 1-(methylsulfonyl)-4-[[4-(phenylmethyl)-5-[1-(2-pyridinyl)-4-  
 piperidinyl]-4H-1,2,4-triazol-3-yl]methyl]- (9CI) (CA INDEX NAME)



=> d all hitstr l16 tot

L16 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2005:76225 HCAPLUS

DN 142:148824

ED Entered STN: 28 Jan 2005

TI Triazolyl compound vasopressin V1a receptor antagonists for the treatment  
 of male sexual dysfunction, and screening assays

IN Wayman, Christopher Peter; Russell, Rachel Jane

PA Pfizer Limited, UK; Pfizer Inc.

SO PCT Int. Appl., 74 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A41K031-41

ICS A61P015-12

CC 1-12 (Pharmacology)

Section cross-reference(s): 2

FAN.CNT 1

| PATENT NO. | KIND | DATE  | APPLICATION NO. | DATE  |
|------------|------|-------|-----------------|-------|
| -----      | ---- | ----- | -----           | ----- |



PI WO 2005006899 A1 20050127 WO 2004-IB2300 20040712  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
 SN, TD, TG

PRAI WO 2003-IB17227 A 20030723

## CLASS

| PATENT NO.    | CLASS | PATENT FAMILY CLASSIFICATION CODES |
|---------------|-------|------------------------------------|
| WO 2005006899 | ICM   | A41K031-41                         |
|               | ICS   | A61P015-12                         |
| WO 2005006899 | ECLA  | A61K031/41; A61K031/4196           |

OS MARPAT 142:148824

AB The invention discloses the use of antagonists of vasopressin V1a receptors for the treatment of male sexual dysfunction, in particular ejaculatory disorders, such as premature ejaculation or rapid ejaculation. The invention also discloses a method for treatment of male sexual dysfunction, in particular ejaculatory disorders, such as premature ejaculation or rapid ejaculation. The invention invention further discloses assays to screen for compds. useful in the treatment of male sexual dysfunction, in particular ejaculatory disorders, such as premature ejaculation or rapid ejaculation, by screening for compds. which are V1a receptor antagonists. Compds. of the invention include e.g. 4-[4-benzyl-5-(4-methoxypiperidin-1-ylmethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl.

ST Vasopressin V1a receptor antagonist male sexual dysfunction treatment; premature rapid ejaculation treatment Vasopressin V1a receptor antagonist; screening Vasopressin V1a receptor antagonist male sexual dysfunction treatment; triazolyl compd Vasopressin V1a antagonist male sexual dysfunction treatment

IT Vasopressin receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (V1a; triazolyl compound vasopressin V1a receptor antagonists for treatment of male sexual dysfunction, and screening assays)

IT 5-HT reuptake inhibitors

(combination; vasopressin V1a receptor antagonists for treatment of male sexual dysfunction, and screening assays)

IT Sexual behavior

(disorder; vasopressin V1a receptor antagonists for treatment of male sexual dysfunction, and screening assays)

IT Sexual behavior

(ejaculation, rapid; vasopressin V1a receptor antagonists for treatment of male sexual dysfunction, and screening assays)

IT Drug delivery systems

(injections, i.v.; vasopressin V1a receptor antagonists for treatment of male sexual dysfunction, and screening assays)

IT Sexual behavior

(premature ejaculation; vasopressin V1a receptor antagonists for treatment of male sexual dysfunction, and screening assays)

IT Radiochemical analysis

(receptor-binding; vasopressin V1a receptor antagonists for treatment of male sexual dysfunction, and screening assays)

IT Drug delivery systems

(tablets; vasopressin V1a receptor antagonists for treatment of male sexual dysfunction, and screening assays)

IT Combination chemotherapy

Drug delivery systems

Drug screening

Human

## Second messenger system

(vasopressin V1a receptor antagonists for treatment of male sexual dysfunction, and screening assays)

IT 9068-52-4, Phosphodiesterase V

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(inhibitors, combination; vasopressin V1a receptor antagonists for treatment of male sexual dysfunction, and screening assays)IT 288-88-0D, 1H-1,2,4-Triazole, derivs. 162042-44-6, L 371257  
685827-24-1RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(vasopressin V1a receptor antagonists for treatment of male sexual dysfunction, and screening assays)

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Pfizer Ltd; WO 2004037809 A 2004 HCAPLUS


(2) Tobe, T; WO 0158880 A 2001 HCAPLUS

IT 685827-24-1

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(vasopressin V1a receptor antagonists for treatment of male sexual dysfunction, and screening assays)

RN 685827-24-1 HCAPLUS

CN Pyridine, 2-[4-[5-[(4-methoxy-1-piperidinyl)methyl]-4-(phenylmethyl)-4H-1,2,4-triazol-3-yl]-1-piperidinyl]- (9CI) (CA INDEX NAME)



L16 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2001:851132 HCAPLUS

DN 136:5994

ED Entered STN: 23 Nov 2001

TI Preparation of triazole derivatives as glycine transporter inhibitors  
useful as learning improving agentsIN Tobe, Takahiko; Sugane, Takashi; Hamaguchi, Wataru; Shimada, Itsuro;  
Maeno, Kyoichi; Miyata, Junji; Kimizuka, Tetsuya; Suzuki, Takeshi; Kohara,  
Atsuyuki; Morita, Takuma; Arlt, Michael; Greiner, HartmutPA Yamanouchi Pharmaceutical Co., Ltd., Japan; Merck Patent Gesellschaft mit  
Beschränkter Haftung

SO PCT Int. Appl., 68 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

IC ICM C07D249-08

ICS C07D249-12; C07D401-04; C07D413-14; C07D405-14; C07D405-12;  
C07D405-04; C07D403-04; C07D413-04; C07D409-10; C07D417-10;  
C07D401-10; C07D401-14; C07D405-10; C07D401-16; C07D401-12;  
C07D495-04; A61K031-41; A61K031-4439; A61K031-4155

CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

FAN.CNT 1

| PATENT NO.   | KIND | DATE     | APPLICATION NO. | DATE     |
|--|------|----------|-----------------|----------|
| WO 2001087855  | A1   | 20011122 | WO 2001-JP4128  | 20010517 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,<br>CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,<br>GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, |      |          |                 |          |

LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,  
 RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,  
 VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

|  |    |          |                 |          |
|--|----|----------|-----------------|----------|
| AU 2001056769  | A5 | 20011126 | AU 2001-56769   | 20010517 |
| CA 2409819   | AA | 20021118 | CA 2001-2409819 | 20010517 |
| EP 1293503   | A1 | 20030319 | EP 2001-930192  | 20010517 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,<br>IE, SI, LT, LV, FI, RO, MK, CY, AL, TR |    |          |                 |          |
| BR 2001010961  | A  | 20040629 | BR 2001-10961   | 20010517 |
| NO 2002005517  | A  | 20021118 | NO 2002-5517    | 20021118 |
| US 2003216385  | A1 | 20031120 | US 2002-276720  | 20021118 |
| ZA 2002010245  | A  | 20040318 | ZA 2002-10245   | 20021218 |
| US 2004214818  | A1 | 20041028 | US 2004-848386  | 20040519 |
| PRAI JP 2000-148419  | A  | 20000519 |                 |          |
| JP 2001-47921  | A  | 20010223 |                 |          |
| WO 2001-JP4128   | W  | 20010517 |                 |          |
| US 2002-276720   | A3 | 20021118 | ✓               |          |



## CLASS

| PATENT NO.    | CLASS       | PATENT FAMILY CLASSIFICATION CODES  |
|---------------|-------------|---|
| WO 2001087855 | ICM<br>ICS  | C07D249-08<br>C07D249-12; C07D401-04; C07D413-14; C07D405-14;<br>C07D405-12; C07D405-04; C07D403-04; C07D413-04;<br>C07D409-10; C07D417-10; C07D401-10; C07D401-14;<br>C07D405-10; C07D401-16; C07D401-12; C07D495-04;<br>A61K031-41; A61K031-4439; A61K031-4155  |
| WO 2001087855 | ECLA        | A61K031/41; A61K031/4155; A61K031/416; A61K031/427;<br>A61K031/4439; A61K031/4709; A61K031/4725; A61K031/517;<br>A61K031/5377; C07D249/08C3; C07D249/10; C07D249/12;<br>C07D249/14; C07D401/04+249B+217; C07D401/04+249B+215;<br>C07D401/04+249B+211; C07D401/06+249B+215;<br>C07D401/06+249B+217; C07D401/10+249B+215;<br>C07D401/14+249B+215+213; C07D403/04+249B+231;<br>C07D403/04+249B+207; C07D403/04+249B+209C;<br>C07D403/04+249B+235C; C07D403/10+249B+233;<br>C07D403/10+257+249B; C07D405/04+307B+249B;<br>C07D405/06+309+249B; C07D405/10+307+249B;<br>C07D405/12+307B+249B; C07D405/12+309+249B;<br>C07D405/14+307B+249B+213; C07D405/14+309+249B+213;<br>C07D405/14+307B+249B+215+213; C07D409/10+333B+249B;<br>C07D413/04+271+249B; C07D413/14+271+249B+2157;<br>C07D417/04+285B+249B; C07D417/10+277B+249B;<br>C07D495/04+333B+221B |
| EP 1293503    | ECLA        | C07D249/10; C07D405/10+307+249B; C07D405/12+307B+249B;<br>C07D405/12+309+249B; C07D405/14+307B+249B+213;<br>C07D405/14+309+249B+213; C07D405/14+307B+249B+215+213;<br>C07D409/10+333B+249B; C07D413/04+271+249B;<br>C07D413/14+271+249B+2157; C07D417/04+285B+249B;<br>C07D417/10+277B+249B; C07D495/04+333B+221B; C07D249/12;<br>C07D249/14; C07D401/04+249B+217; C07D401/04+249B+215;<br>C07D401/04+249B+211; C07D401/06+249B+215;<br>C07D401/06+249B+217; C07D401/10+249B+215;<br>C07D401/12+309+213; C07D401/14+249B+215+213;<br>C07D403/04+249B+231; C07D403/04+249B+207;<br>C07D403/04+249B+209C; C07D403/04+249B+235C;<br>C07D403/10+249B+233; C07D403/10+257+249B;<br>C07D405/04+307B+249B; C07D405/06+309+249B; C07D249/08C3   |
| US 2003216385 | NCL<br>ECLA | 514/227.800<br>A61K031/41; C07D403/04+249B+207; C07D403/04+249B+231;<br>C07D403/10+249B+233; C07D403/10+257+249B;<br>C07D405/04+307B+249B; C07D405/06+309+249B;<br>C07D405/10+307+249B; C07D405/12+309+249B;<br>C07D405/12+307B+249B; C07D405/14+307B+249B+215+213;   |

US 2004214818 NCL  
ECLA

C07D405/14+309+249B+213; C07D405/14+307B+249B+213;  
C07D409/10+333B+249B; C07D413/04+271+249B;  
C07D413/14+271+249B+2157; C07D417/04+285B+249B;  
C07D417/10+277B+249B; C07D495/04+333B+221B;  
A61K031/4155; A61K031/416; A61K031/427; A61K031/4439;  
A61K031/4709; A61K031/4725; A61K031/517; A61K031/5377;  
C07D249/08C3; C07D249/10; C07D249/12; C07D249/14;  
C07D401/04+249B+211; C07D401/04+249B+215;  
C07D401/04+249B+217; C07D401/06+249B+217;  
C07D401/06+249B+215; C07D401/10+249B+215;  
C07D401/12+309+213; C07D401/14+249B+215+213;  
C07D403/04+249B+235C; C07D403/04+249B+209C  
514/217.090  
A61K031/41; A61K031/4155; A61K031/416; A61K031/427;  
A61K031/4439; A61K031/4709; A61K031/4725; A61K031/517;  
A61K031/5377; C07D249/08C3; C07D249/10; C07D249/12;  
C07D249/14; C07D401/04+249B+211; C07D401/04+249B+215;  
C07D401/04+249B+217; C07D401/06+249B+215;  
C07D401/06+249B+217; C07D401/10+249B+215;  
C07D401/12+309+213; C07D401/14+249B+215+213;  
C07D403/04+249B+207; C07D403/04+249B+209C;  
C07D403/04+249B+231; C07D403/04+249B+235C;  
C07D403/10+249B+233; C07D403/10+257+249B;  
C07D405/04+307B+249B; C07D405/06+309+249B;  
C07D405/10+307+249B; C07D405/12+307B+249B;  
C07D405/12+309+249B; C07D405/14+307B+249B+213;  
C07D405/14+307B+249B+215+213; C07D405/14+309+249B+213;  
C07D409/10+333B+249B; C07D413/04+271+249B;  
C07D413/14+271+249B+2157; C07D417/04+285B+249B;  
C07D417/10+277B+249B; C07D495/04+333B+221B

OS MARPAT 136:5994  
GI



AB Title compds. [I; A = aryl, heterocycly, cycloalkyl; B = aryl, pyridyl; D = aryl; R = H, CH<sub>3</sub>, CH<sub>3</sub>CH<sub>2</sub>, (CH<sub>3</sub>)<sub>2</sub>CH, CH<sub>3</sub>(CH<sub>2</sub>)<sub>2</sub>, CH<sub>3</sub>O(CH<sub>2</sub>)<sub>3</sub>, CH<sub>3</sub>CH<sub>2</sub>NH, (CH<sub>3</sub>)<sub>2</sub>N, CH<sub>3</sub>OCH<sub>2</sub>CH<sub>2</sub>NH], having glycine transporter inhibitory activity, are prepared for remedies as learning improving agents. Thus, the title compound (II) was prepared and biol. tested.

ST triazole prepn glycine transporter inhibitor learning improvement agent

IT Learning  
(preparation of triazole derivs. as glycine transporter inhibitors useful as learning improving agents)

IT 374886-50-7P 374886-51-8P 374886-54-1P 374886-55-2P 374886-57-4P  
 374886-58-5P 374886-59-6P 374887-58-8P 374888-00-3P 374888-44-5P  
 374888-78-5P 374888-97-8P 374889-20-0P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of triazole derivs. as glycine transporter inhibitors)

IT 348-54-9, 2-Fluoroaniline 611-34-7, 5-Quinolinamine 615-36-1,  
 2-Bromoaniline 626-55-1, 3-Bromopyridine 5933-32-4 6165-68-0,  
 2-Thienylboric acid 18622-23-6 29006-02-8 29051-44-3,  
 6-Phenylnicotinic acid 30379-55-6, Benzyloxyacetic acid 38256-93-8  
 38985-64-7, 2-Fluorophenylisothiocyanate 51362-48-2 135063-40-0  
 290366-59-5 374889-84-6 374889-87-9 374889-91-5 374889-98-2  
 374890-01-4  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of triazole derivs. as glycine transporter inhibitors)

IT 197079-04-2P 349129-99-3P 374889-30-2P 374889-31-3P 374889-32-4P  
 374889-33-5P 374889-34-6P 374889-35-7P 374889-36-8P 374889-37-9P  
 374889-38-0P 374889-39-1P 374889-40-4P 374889-41-5P 374889-42-6P  
 374889-43-7P 374889-44-8P 374889-45-9P 374889-46-0P 374889-47-1P  
 374889-48-2P 374889-49-3P 374889-50-6P 374889-51-7P 374889-52-8P  
 374889-53-9P 374889-54-0P 374889-55-1P 374889-56-2P 374889-57-3P  
 374889-58-4P 374889-59-5P 374889-60-8P 374889-61-9P 374889-62-0P  
 374889-63-1P 374889-64-2P 374889-65-3P 374889-66-4P 374889-67-5P  
 374889-68-6P 374889-69-7P 374889-70-0P 374889-71-1P 374889-72-2P  
 374889-73-3P 374889-74-4P 374889-75-5P 374889-76-6P 374889-77-7P  
 374889-78-8P 374889-79-9P 374889-80-2P 374889-81-3P 374889-82-4P  
 374889-83-5P 374889-85-7P 374889-86-8P 374889-88-0P 374889-89-1P  
 374889-90-4P 374889-92-6P 374889-93-7P 374889-94-8P 374889-95-9P  
 374889-96-0P 374889-97-1P 374889-99-3P 374890-00-3P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of triazole derivs. as glycine transporter inhibitors)

IT 374886-53-0P 374886-56-3P 374886-62-1P 374886-63-2P 374886-64-3P  
 374888-08-1P  
 RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of triazole derivs. as glycine transporter inhibitors)

IT 374886-52-9P 374886-60-9P 374886-61-0P 374886-65-4P 374886-66-5P  
 374886-67-6P 374886-68-7P 374886-69-8P 374886-70-1P 374886-71-2P  
 374886-72-3P 374886-73-4P 374886-74-5P 374886-75-6P 374886-76-7P  
 374886-77-8P 374886-78-9P 374886-79-0P 374886-80-3P 374886-81-4P  
 374886-82-5P 374886-83-6P 374886-84-7P 374886-85-8P 374886-86-9P  
 374886-87-0P 374886-88-1P 374886-89-2P 374886-90-5P 374886-91-6P  
 374886-92-7P 374886-93-8P 374886-94-9P 374886-95-0P 374886-96-1P  
 374886-97-2P 374886-98-3P 374886-99-4P 374887-00-0P 374887-01-1P  
 374887-02-2P 374887-03-3P 374887-04-4P 374887-05-5P 374887-06-6P  
 374887-07-7P 374887-08-8P 374887-09-9P 374887-10-2P 374887-11-3P  
 374887-12-4P 374887-13-5P 374887-14-6P 374887-15-7P  
 374887-16-8P 374887-17-9P 374887-18-0P 374887-19-1P  
 374887-20-4P 374887-21-5P 374887-22-6P 374887-23-7P 374887-24-8P  
 374887-25-9P 374887-26-0P 374887-27-1P 374887-28-2P 374887-29-3P  
 374887-30-6P 374887-31-7P 374887-32-8P 374887-33-9P 374887-34-0P  
 374887-35-1P 374887-36-2P 374887-37-3P 374887-38-4P 374887-39-5P  
 374887-40-8P 374887-41-9P 374887-42-0P 374887-43-1P 374887-44-2P  
 374887-45-3P 374887-46-4P 374887-47-5P 374887-48-6P 374887-49-7P  
 374887-50-0P 374887-51-1P 374887-52-2P 374887-53-3P 374887-54-4P  
 374887-55-5P 374887-56-6P 374887-57-7P 374887-59-9P 374887-60-2P  
 374887-61-3P 374887-62-4P 374887-63-5P 374887-64-6P 374887-65-7P  
 374887-66-8P 374887-67-9P 374887-68-0P 374887-69-1P 374887-70-4P  
 374887-71-5P 374887-72-6P 374887-73-7P 374887-74-8P 374887-75-9P  
 374887-76-0P 374887-77-1P 374887-78-2P 374887-79-3P 374887-80-6P  
 374887-81-7P 374887-82-8P 374887-83-9P 374887-84-0P 374887-85-1P  
 374887-86-2P 374887-87-3P 374887-88-4P 374887-89-5P 374887-90-8P  
 374887-91-9P 374887-92-0P 374887-93-1P 374887-94-2P 374887-95-3P

|              |              |              |              |              |
|--------------|--------------|--------------|--------------|--------------|
| 374887-96-4P | 374887-97-5P | 374887-98-6P | 374887-99-7P | 374888-01-4P |
| 374888-02-5P | 374888-03-6P | 374888-04-7P | 374888-05-8P | 374888-06-9P |
| 374888-07-0P | 374888-09-2P | 374888-10-5P | 374888-11-6P | 374888-12-7P |
| 374888-13-8P | 374888-14-9P | 374888-15-0P | 374888-16-1P | 374888-17-2P |
| 374888-18-3P | 374888-19-4P | 374888-20-7P | 374888-21-8P | 374888-22-9P |
| 374888-23-0P | 374888-24-1P | 374888-25-2P | 374888-26-3P | 374888-27-4P |
| 374888-28-5P | 374888-29-6P | 374888-30-9P | 374888-31-0P | 374888-32-1P |
| 374888-33-2P | 374888-34-3P | 374888-35-4P | 374888-36-5P | 374888-37-6P |
| 374888-38-7P | 374888-39-8P | 374888-40-1P | 374888-41-2P | 374888-42-3P |
| 374888-43-4P | 374888-45-6P | 374888-46-7P | 374888-47-8P | 374888-48-9P |
| 374888-49-0P | 374888-50-3P | 374888-51-4P | 374888-52-5P | 374888-53-6P |
| 374888-54-7P | 374888-55-8P | 374888-56-9P | 374888-57-0P | 374888-58-1P |
| 374888-59-2P | 374888-60-5P | 374888-61-6P | 374888-62-7P | 374888-63-8P |
| 374888-64-9P | 374888-65-0P | 374888-66-1P | 374888-67-2P | 374888-68-3P |
| 374888-69-4P | 374888-70-7P | 374888-71-8P | 374888-72-9P | 374888-73-0P |
| 374888-74-1P | 374888-75-2P | 374888-76-3P | 374888-77-4P | 374888-79-6P |
| 374888-80-9P | 374888-81-0P | 374888-82-1P | 374888-83-2P | 374888-84-3P |
| 374888-85-4P | 374888-86-5P | 374888-87-6P | 374888-88-7P | 374888-89-8P |
| 374888-90-1P | 374888-91-2P | 374888-92-3P | 374888-93-4P | 374888-94-5P |
| 374888-95-6P | 374888-96-7P | 374888-98-9P | 374888-99-0P | 374889-00-6P |
| 374889-01-7P | 374889-02-8P |              |              |              |

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of triazole derivs. as glycine transporter inhibitors)

|    |              |              |              |              |              |
|----|--------------|--------------|--------------|--------------|--------------|
| IT | 374889-03-9P | 374889-04-0P | 374889-05-1P | 374889-06-2P | 374889-07-3P |
|    | 374889-08-4P | 374889-09-5P | 374889-10-8P | 374889-11-9P | 374889-12-0P |
|    | 374889-13-1P | 374889-14-2P | 374889-15-3P | 374889-16-4P | 374889-17-5P |
|    | 374889-18-6P | 374889-19-7P | 374889-21-1P | 374889-22-2P | 374889-23-3P |
|    | 374889-24-4P | 374889-25-5P | 374889-26-6P | 374889-27-7P | 374889-28-8P |
|    | 374889-29-9P | 374890-03-6P | 374890-04-7P | 374890-05-8P | 374890-06-9P |
|    | 374890-07-0P |              |              |              |              |

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of triazole derivs. as glycine transporter inhibitors)

RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Boehringer Ingelheim Kg; JP 01275571 A HCAPLUS
- (2) Boehringer Ingelheim Kg; DE 3808283 A HCAPLUS
- (3) Boehringer Ingelheim Kg; EP 335144 A 1989 HCAPLUS
- (4) Dr Kahl Thomae GmbH; DE 4302051 A HCAPLUS
- (5) Dr Kahl Thomae GmbH; JP 72851 A
- (6) Dr Kahl Thomae GmbH; EP 608858 A 1994 HCAPLUS
- (7) Pfizer Research And Development Company N VS A; JP 11506123 A
- (8) Pfizer Research And Development Company N VS A; EP 885212 A HCAPLUS
- (9) Pfizer Research And Development Company N VS A; WO 9732873 A 1997 HCAPLUS
- (10) Yamanouchi Pharmaceutical Co Ltd; JP 200063363 A 2000


IT 374887-14-6P 374887-16-8P 374887-17-9P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)



(preparation of triazole derivs. as glycine transporter inhibitors)

RN 374887-14-6 HCAPLUS


CN Piperidine, 1-[5-ethyl-4-(2-fluorophenyl)-4H-1,2,4-triazol-3-yl]-4-phenyl-(9CI) (CA INDEX NAME)



RN 374887-16-8 HCAPLUS  
 CN Piperidine, 4-[5-ethyl-4-(2-fluorophenyl)-4H-1,2,4-triazol-3-yl]-1-phenyl-  
 (9CI) (CA INDEX NAME)



RN 374887-17-9 HCAPLUS  
 CN Piperazine, 1-[5-ethyl-4-(2-fluorophenyl)-4H-1,2,4-triazol-3-yl]-4-phenyl-  
 (9CI) (CA INDEX NAME)



=> b uspatall  
 FILE 'USPATFULL' ENTERED AT 09:24:59 ON 22 SEP 2005  
 CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 09:24:59 ON 22 SEP 2005

Search done by Noble Jarrell

CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

=&gt; d bib abs fhitrn hitrn l17 tot

✓ L17 ANSWER 1 OF 3 USPATFULL on STN  
 AN 2005:31373 USPATFULL  
 TI Treatment of male sexual dysfunction  
 IN Wayman, Christopher Peter, Sandwich, UNITED KINGDOM  
 Russell, Rachel Jane, Sandwich, UNITED KINGDOM  
 PA Pfizer Inc. (non-U.S. corporation)  
 PI US 2005026810 A1 20050203  
 AI US ~~2004-895630~~ A1 20040720 (10)  
 PRAI GB 2003-17227 20030723  
 US 2003-493823P 20030808 (60)  
 DT Utility  
 FS APPLICATION  
 LREP PFIZER INC., PATENT DEPARTMENT, MS8260-1611, EASTERN POINT ROAD, GROTON,  
 CT, 06340  
 CLMN Number of Claims: 16  
 ECL Exemplary Claim: 1  
 DRWN 1 Drawing Page(s)  
 LN.CNT 2348


10 895630

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates the use of antagonists of vasopressin V1a receptors for the treatment of male sexual dysfunction, in particular ejaculatory disorders, such as premature ejaculation or rapid ejaculation. The present invention also relates to a method of treatment of male sexual dysfunction, in particular ejaculatory disorders, such as premature ejaculation or rapid ejaculation. The present invention also relates to assays to screen for compounds useful in the treatment of male sexual dysfunction, in particular ejaculatory disorders, such as premature ejaculation or rapid ejaculation, by screening for compounds which are V1a receptor antagonists.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 748806-15-7P, [4-Chloro-2-[1-[[[4-(4-chlorophenyl)-5-[1-(pyrimidin-2-yl)piperidin-4-yl]-4H-[1,2,4]triazol-3-yl]methyl]methylamino]ethyl]phenyl]amine  
 (intermediate; preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)  
 RN 748806-15-7 USPATFULL  
 CN 4H-1,2,4-Triazole-3-methanamine, N-[1-(2-amino-5-chlorophenyl)ethyl]-4-(4-chlorophenyl)-N-methyl-5-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



IT 748806-15-7P, [4-Chloro-2-[1-[[[4-(4-chlorophenyl)-5-[1-(pyrimidin-2-yl)piperidin-4-yl]-4H-[1,2,4]triazol-3-yl]methyl]methylamino]ethyl]phenyl]amine  
 (intermediate; preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)



for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Sep 2005 VOL 143 ISS 13  
FILE LAST UPDATED: 21 Sep 2005 (20050921/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all fhitr 115 tot

L15 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2005 ACS on STN  
AN 2004:718543 HCAPLUS  
DN 141:225517  
ED Entered STN: 02 Sep 2004  
TI Preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea  
IN Bryans, Justin Stephen; Johnson, Patrick Stephen; Ryckmans, Thomas; Stobie, Alan  
PA Pfizer Limited, UK; Pfizer Inc.  
SO PCT Int. Appl., 164 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
IC ICM C07D487-04  
ICS A61K031-55; A61K031-501; A61K031-4427; A61P029-00; C07D498-04; C07D401-04; C07D413-14; C07D513-04; C07D249-00; C07D243-00; C07D267-00  
CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))  
Section cross-reference(s): 1, 63  
FAN.CNT 1

| PATENT NO.  | KIND | DATE     | APPLICATION NO. | DATE     |
|---|------|----------|-----------------|----------|
| WO 2004074291   | A1   | 20040902 | WO 2004-IB432   | 20040209 |
| W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI<br>RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG |      |          |                 |          |
| US 2004186091   | A1   | 20040923 | US 2004-782285  | 20040218 |
| NL 1025527  | A1   | 20040823 | NL 2004-1025527 | 20040219 |
| NL 1025527  | C2   | 20050314 |                 |          |
| US 2005026810   | A1   | 20050203 | US 2004-895630  | 20040720 |
| PRAI GB 2003-3852   | A    | 20030219 |                 |          |
| GB 2003-17227   | A    | 20030723 |                 |          |
| US 2003-455455P   | P    | 20030318 |                 |          |
| US 2003-493823P   | P    | 20030808 |                 |          |

CLASS  
PATENT NO. CLASS PATENT FAMILY CLASSIFICATION CODES  
-----  
WO 2004074291 ICM C07D487-04  
ICS A61K031-55; A61K031-501; A61K031-4427; A61P029-00;

✓  
L17 ANSWER 2 OF 3 USPATFULL on STN  
AN 2004:240276 USPATFULL  
TI Triazole compounds useful in therapy  
IN Bryans, Justin Stephen, Sandwich, UNITED KINGDOM  
Johnson, Patrick Stephen, Sandwich, UNITED KINGDOM  
Ryckmans, Thomas, Sandwich, UNITED KINGDOM  
Stobie, Alan, Sandwich, UNITED KINGDOM  
PA Pfizer Inc (non-U.S. corporation)  
PI US 2004186091 A1 20040923  
AI US 2004-782285 A1 20040218 (10)  
PRAI GB 2003-3852 20030219  
US 2003-455455P 20030318 (60)  
DT Utility  
FS APPLICATION  
LREP PFIZER INC., PATENT DEPARTMENT, MS8260-1611, EASTERN POINT ROAD, GROTON,  
CT, 06340  
CLMN Number of Claims: 26  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 4730  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB A compound of formula (I), ##STR1##

or a pharmaceutically acceptable derivative thereof, wherein

V represents --(CH.sub.2).sub.d(O).sub.e--, --CO--, or --CH(C.sub.1-6 alkyl)-;

W is --O--, --S(O).sub.a--, or --N(R.sup.1)--

R.sup.1 represents H, C.sub.1-6 alkyl, (CH.sub.2).sub.bCOR.sup.2, CO(CH.sub.2).sub.bNR.sup.2R.sup.3, SO.sub.2R.sup.2, (CH.sub.2).sub.cOR.sup.2, (CH.sub.2).sub.cNR.sup.2R.sup.3, or (CH.sub.2).sub.bhet.sup.1;

het.sup.1 represents a saturated or unsaturated heterocycle of from 3 to 8 atoms containing one or more heteroatoms selected from O, N, or S, optionally substituted with C.sub.1-6 alkyl;

X and Y independently represent H, C.sub.1-6 alkyl, halogen, OH, CF.sub.3, OCF.sub.3, OR.sup.4;

Z represents --(CH.sub.2).sub.f(O).sub.g--, --CO-- or --CH(C.sub.1-6 alkyl)-;

Ring A represents a 4-7 membered, saturated N-containing heterocycle, optionally substituted with OH, and in which optionally at least one ring N is substituted with O;

Ring B represents phenyl or a 4-7 membered unsaturated N-containing heterocycle, optionally substituted with OH, halogen, CN, CONH.sub.2, CF.sub.3, OCF.sub.3, and in which optionally at least one ring N is substituted with O;

R.sup.2 and R.sup.3 independently represent H, C.sub.1-6 alkyl [optionally substituted with OH, halogen, N(C.sub.1-6 alkyl).sub.2, or C.sub.1-6 alkyloxy], C.sub.1-6 alkyloxy, N(C.sub.1-6 alkyl).sub.2, or [C.sub.3-8 cycloalkyl];

or R.sup.2 and R.sup.3, together with the nitrogen atom to which they are attached independently represent a heterocycle of from 3 to 8 atoms, optionally substituted with C.sub.1-6 alkyl;

R.sup.4 represents straight or branched C.sub.1-6 alkyl,

a and c independently represent 0, 1, or 2;

b, e and g independently represent 0 or 1;

d and f independently represent 1 or 2;


are useful in the treatment of dysmenorrhoea

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 748806-15-7P, [4-Chloro-2-[1-[[[4-(4-chlorophenyl)-5-[1-(pyrimidin-2-yl)piperidin-4-yl]-4H-[1,2,4]triazol-3-yl]methyl]methylamino]ethyl]phenyl]amine  
(intermediate; preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)

RN 748806-15-7 USPATFULL

CN 4H-1,2,4-Triazole-3-methanamine, N-[1-(2-amino-5-chlorophenyl)ethyl]-4-(4-chlorophenyl)-N-methyl-5-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



IT 748806-15-7P, [4-Chloro-2-[1-[[[4-(4-chlorophenyl)-5-[1-(pyrimidin-2-yl)piperidin-4-yl]-4H-[1,2,4]triazol-3-yl]methyl]methylamino]ethyl]phenyl]amine  
(intermediate; preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)

L17 ANSWER 3 OF 3 USPATFULL on STN

AN 2004:209844 USPATFULL

TI Triazole compounds useful in therapy

IN Armour, Robert Duncan, Sandwich, UNITED KINGDOM

Baxter, Andrew Douglas, Sandwich, UNITED KINGDOM

Bryans, Justin Stephen, Sandwich, UNITED KINGDOM

Dack, Kevin Neil, Sandwich, UNITED KINGDOM

Johnson, Patrick Stephen, Sandwich, UNITED KINGDOM

Lewthwaite, Russell Andrew, Sandwich, UNITED KINGDOM

Newman, Julie, Sandwich, UNITED KINGDOM

Rawson, David James, Sandwich, UNITED KINGDOM

Ryckmans, Thomas, Sandwich, UNITED KINGDOM

PA Pfizer Inc (non-U.S. corporation)

PI US 2004162278 A1 20040819

AI US 2003-693327 A1 20031024 (10)

PRAI GB 2002-24919 20021025

US 2002-428632P 20021122 (60)

DT Utility

FS APPLICATION

LREP PFIZER INC., PATENT DEPARTMENT, MS8260-1611, EASTERN POINT ROAD, GROTON, CT, 06340

CLMN Number of Claims: 21

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 3402

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides compounds of formula (I), ##STR1##

Search done by Noble Jarrell


the pharmaceutically acceptable salts and solvates thereof, wherein A, B, R.sup.1, R.sup.2, and R.sup.7 are as defined herein; pharmaceutical compositions thereof; combinations thereof; and uses thereof as vasopressin V.sub.1A antagonists.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 685827-43-4P, 4-[4-Benzyl-5-[4-(methanesulfonyl)piperazin-1-ylmethyl]-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl (V1A receptor antagonist, V1a receptor antagonist; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

RN 685827-43-4 USPATFULL

CN Piperazine, 1-(methylsulfonyl)-4-[[4-(phenylmethyl)-5-[1-(2-pyridinyl)-4-piperidinyl]-4H-1,2,4-triazol-3-yl]methyl]- (9CI) (CA INDEX NAME)



IT 685827-43-4P, 4-[4-Benzyl-5-[4-(methanesulfonyl)piperazin-1-ylmethyl]-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl (V1A receptor antagonist, V1a receptor antagonist; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT 685827-36-5P, 4-[4-(3-Chlorobenzyl)-5-methyl-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-69-4P, 4-[4-Benzyl-5-(2-oxa-5-azabicyclo[2.2.1]hept-5-ylmethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl (V1A receptor antagonist; preparation of triazoles as V1a receptor antagonists for treatment of dysmenorrhea)

IT 685827-26-3P, Benzyl 4-[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl]piperazine-1-carboxylate (V1a receptor antagonist, intermediate; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT 685826-99-7P, (S)-4-[5-Butyl-4-(1-phenylethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-00-3P, 2-[4-(4-Benzyl-5-isobutyl-4H-[1,2,4]triazol-3-yl)piperidin-1-yl]pyrimidine 685827-01-4P, (S)-4-[5-Methyl-4-(1-phenylethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-02-5P, 4-(4-Benzyl-5-butyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-03-6P, 2-[4-(4-Benzyl-5-isopropyl-4H-[1,2,4]triazol-3-yl)piperidin-1-yl]pyrimidine 685827-05-8P, (S)-2-[4-[5-Methyl-4-(1-phenylpropyl)-4H-[1,2,4]triazol-3-yl]piperidin-1-yl]pyrimidine 685827-06-9P, 2-[4-(4-Benzyl-5-propyl-4H-[1,2,4]triazol-3-yl)piperidin-1-yl]pyrimidine 685827-07-0P, 2-[4-[4-Benzyl-5-(2-chlorophenoxymethyl)-4H-[1,2,4]triazol-3-yl]piperidin-1-yl]pyrimidine 685827-08-1P, 2-[4-(4-Benzyl-5-butyl-4H-[1,2,4]triazol-3-yl)piperidin-1-yl]pyrimidine 685827-09-2P, (S)-2-[4-[5-Methyl-4-(1-phenylethyl)-4H-[1,2,4]triazol-3-yl]piperidin-1-yl]pyrimidine 685827-10-5P, 2-[4-[4-Benzyl-5-(4-fluorophenoxymethyl)-4H-[1,2,4]triazol-3-yl]piperidin-1-yl]pyrimidine 685827-11-6P, 2-[4-[5-Methyl-4-(3-methylbenzyl)-4H-[1,2,4]triazol-3-yl]piperidin-1-yl]pyrimidine 685827-12-7P, (S)-2-[4-[5-Methyl-4-(1-phenylethyl)-4H-[1,2,4]triazol-3-ylmethyl]piperidin-1-yl]pyrimidine 685827-13-8P, 2-[4-[4-(3-Fluorobenzyl)-5-methyl-4H-[1,2,4]triazol-3-yl]piperidin-1-yl]pyrimidine 685827-14-9P, 4-(4-Benzyl-5-[(morpholin-4-yl)methyl]-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-15-0P, 4-[4-Benzyl-5-[(benzyloxy)methyl]-4H-[1,2,4]triazol-3-yl]-3,4,5,6-

tetrahydro-2H-[1,2']bipyridinyl 685827-16-1P,  
4-(4-Benzyl-5-methyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-  
[1,2']bipyridinyl 685827-17-2P, (R)-2-[3-Methyl-5-[1-(pyrimidin-  
2-yl)piperidin-4-yl]-[1,2,4]triazol-4-yl]-2-phenylethanol  
685827-19-4P, 2-[4-(4-Benzyl-5-methyl-4H-[1,2,4]triazol-3-  
yl)piperidin-1-yl]pyrimidine 685827-20-7P, 4-(4-Benzyl-5-methyl-  
4H-[1,2,4]triazol-3-yl)-1-phenylpiperidine 685827-21-8P,  
2-[4-(4-Benzyl-5-methyl-4H-[1,2,4]triazol-3-yl)piperidin-1-yl]pyrazine  
685827-22-9P, 4-(4-Benzyl-5-[(piperidin-1-yl)methyl]-4H-  
[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl  
685827-23-0P, (S)-4-[4-(1-Phenylethyl)-5-[(piperidin-1-yl)methyl]-  
4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl  
685827-24-1P, 4-[4-Benzyl-5-(4-methoxypiperidin-1-ylmethyl)-4H-  
[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl  
685827-25-2P, (S)-4-[5-(4-Methoxypiperidin-1-ylmethyl)-4-(1-  
phenylethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-  
[1,2']bipyridinyl 685827-27-4P, 4-[4-Benzyl-5-[[2-(morpholin-4-  
yl)ethoxy]methyl]-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-  
[1,2']bipyridinyl 685827-28-5P, 4-[4-Benzyl-5-((3R)-3-  
methoxypyrrolidin-1-ylmethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-  
2H-[1,2']bipyridinyl 685827-29-6P 685827-30-9P  
685827-31-0P 685827-32-1P 685827-33-2P  
685827-34-3P 685827-35-4P 685827-37-6P,  
N-Benzyl-2-[4-benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-  
[1,2,4]triazol-3-yl]acetamide 685827-38-7P,  
2-[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-  
[1,2,4]triazol-3-ylmethoxy]ethylamine 685827-39-8P,  
N-[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-  
[1,2,4]triazol-3-ylmethyl]ethylamine 685827-40-1P,  
[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-  
[1,2,4]triazol-3-ylmethyl](2-methoxyethyl)amine 685827-41-2P,  
[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-  
[1,2,4]triazol-3-ylmethyl](3-methoxypropyl)amine 685827-42-3P,  
1-[4-[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-  
[1,2,4]triazol-3-ylmethyl]piperazin-1-yl]ethanone 685827-44-5P,  
N-[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-  
[1,2,4]triazol-3-ylmethyl]methanesulfonamide 685827-45-6P,  
[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-  
[1,2,4]triazol-3-ylmethyl](2-methoxyethyl)methylamine  
685827-46-7P, [4-Benzyl-5-(3,4,5,6-tetrahydro-2H-  
[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl](3-  
methoxypropyl)methylamine 685827-51-4P, (S)-4-[[4-(1-  
Phenylethyl)-5-[4-(pyridin-2-yl)piperazin-1-ylmethyl]-4H-[1,2,4]triazol-3-  
yl]methyl]morpholine trihydrochloride 685827-52-5P,  
(S)-4-[[4-(1-Phenylethyl)-5-[4-(pyrimidin-2-yl)piperazin-1-yl]methyl]-4H-  
[1,2,4]triazol-3-yl]methyl]morpholine trihydrochloride  
685827-53-6P, 1-[[4-Benzyl-5-[1-(pyrimidin-2-yl)piperidin-4-yl]-  
4H-[1,2,4]triazol-3-yl]methyl]piperidin-3-ol 685827-55-8P,  
(R)-4-[4-Benzyl-5-[[4-(tetrahydrofuran-3-yl)oxy]methyl]-4H-[1,2,4]triazol-3-  
yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-56-9P,  
(S)-4-[4-Benzyl-5-[[4-(tetrahydrofuran-3-yl)oxy]methyl]-4H-[1,2,4]triazol-3-  
yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-57-0P,  
[[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-  
[1,2,4]triazol-3-ylmethyl]methylamino]acetic acid tert-butyl ester  
685827-58-1P, 4-[4-Benzyl-5-(tetrahydropyran-4-ylmethyl)-4H-  
[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl  
685827-60-5P, 4-[4-Benzyl-5-(ethoxymethyl)-4H-[1,2,4]triazol-3-  
yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl 685827-61-6P,  
4-[4-Benzyl-5-(2-methoxyethoxymethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-  
tetrahydro-2H-[1,2']bipyridinyl 685827-62-7P,  
[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-  
[1,2,4]triazol-3-ylmethoxy]acetic acid tert-butyl ester  
685827-63-8P, N-Benzyl-2-[4-benzyl-5-(3,4,5,6-tetrahydro-2H-  
[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethoxy]acetamide  
685827-64-9P, 4-[4-Benzyl-5-[(methylsulfanyl)methyl]-4H-  
[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl

685827-65-0P, 4-(4-Benzyl-5-[(pyrazol-1-yl)methyl]-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl  
 685827-66-1P, 4-(4-Benzyl-5-[[[1,2,3]triazol-2-yl)methyl]-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl  
 685827-68-3P, 4-[4-Benzyl-5-(pyridin-4-yloxymethyl)-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl  
 (V1a receptor antagonist; preparation of triazoles as V1a receptor antagonists for the treatment of dysmenorrhea)

IT 685828-31-3P, [4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl]carbamic acid tert-butyl ester  
 685828-32-4P 685828-33-5P 685828-34-6P  
 685828-35-7P, [2-[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethoxy]ethyl]carbamic acid tert-butyl ester 685828-36-8P 685828-37-9P,  
 4-(4-Benzyl-5-[(piperazin-1-yl)methyl]-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl  
 (intermediate; preparation of triazoles as V1a receptor antagonists for treatment of dysmenorrhea)

=> d bib abs hitstr l18 tot

L18 ANSWER 1 OF 2 USPATFULL on STN

AN 2004:274316 USPATFULL

TI Triazole derivative

IN Tobe, Takahiko, Tsukuba-shi, JAPAN  
 Sugane, Takashi, Tsukuba-shi, JAPAN  
 Hamaguchi, Wataru, Tsukuba-shi, JAPAN  
 Shimada, Itsuro, Tsukuba-shi, JAPAN  
 Maeno, Kyoichi, Tsukuba-shi, JAPAN  
 Miyata, Junji, Tsukuba-shi, JAPAN  
 Kimizuka, Tetsuya, Itabashi-ku, JAPAN  
 Suzuki, Takeshi, Tsukuba-shi, JAPAN  
 Kohara, Atsuyuki, Tsukuba-shi, JAPAN  
 Morita, Takuma, Tsukuba-shi, JAPAN

PA Arlt, Michael, Seeheim Jugenheim, GERMANY, FEDERAL REPUBLIC OF  
 Greiner, Hartmut, Weiterstadt, GERMANY, FEDERAL REPUBLIC OF  
 YAMANOUCHI PHARMACEUTICAL CO., LTD., MERCK PATENT GESELLSCHAFT MIT  
 BESCHRANKTER HAFTUNG (non-U.S. corporation)

PI US 2004214818 A1 20041028

AI US 2004-848386 A1 20040519 (10)

RLI Division of Ser. No. US 2002-276720, filed on 18 Nov 2002, PENDING A 371  
 of International Ser. No. WO 2001-JP4128, filed on 17 May 2001, UNKNOWN

PRAI JP 2000-148419 20000519

JP 2001-47921 20010223

DT Utility

FS APPLICATION

LREP SUGHRUE MION, PLLC, 2100 PENNSYLVANIA AVENUE, N.W., SUITE 800,  
 WASHINGTON, DC, 20037

CLMN Number of Claims: 4

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 2464

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a triazole derivative with an activity inhibiting glycine transporter and for use as a pharmaceutical drug, and a novel triazole derivative. The inventive triazole derivative has an excellent activity inhibiting glycine transporter and is useful as a therapeutic agent of dementia, schizophrenia, cognitive disorders, or cognitive disorders involved in various diseases such as Alzheimer disease, Parkinson's disease, or Huntington disease or the like, or spasm involved in diseases such as nerve degenerative diseases and cerebrovascular disorders, or the like. Particularly, the pharmaceutical drug is useful for the amelioration of learning disability of dementia and the like.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 374887-14-6P 374887-16-8P 374887-17-9P

(preparation of triazole derivs. as glycine transporter inhibitors)



RN 374887-14-6 USPATFULL

CN Piperidine, 1-[5-ethyl-4-(2-fluorophenyl)-4H-1,2,4-triazol-3-yl]-4-phenyl-  
(9CI) (CA INDEX NAME)




RN 374887-16-8 USPATFULL

CN Piperidine, 4-[5-ethyl-4-(2-fluorophenyl)-4H-1,2,4-triazol-3-yl]-1-phenyl-  
(9CI) (CA INDEX NAME)




RN 374887-17-9 USPATFULL

CN Piperazine, 1-[5-ethyl-4-(2-fluorophenyl)-4H-1,2,4-triazol-3-yl]-4-phenyl-  
(9CI) (CA INDEX NAME)





L18 ANSWER 2 OF 2 USPATFULL on STN  
 AN 2003:306949 USPATFULL  
 TI Triazole derivatives  
 IN Tobe, Takahiko, Tsukuba-shi, JAPAN  
 Sugane, Takashi, Tsukuba-shi, JAPAN  
 Hamaguchi, Wataru, Tsukuba-shi, JAPAN  
 Shimada, Itsuro, Tsukuba-shi, JAPAN  
 Maeno, Kyoichi, Tsukuba-shi, JAPAN  
 Miyata, Junji, Tsukuba-shi, JAPAN  
 Kimizuka, Tetsuya, Itabashi-ku, JAPAN  
 Suzuki, Takeshi, Tsukuba-shi, JAPAN  
 Kohara, Atsuyuki, Tsukuba-shi, JAPAN  
 Morita, Takuma, Tsukuba-shi, JAPAN  
 Arlt, Michael, Jugenheim, GERMANY, FEDERAL REPUBLIC OF  
 Greiner, Hartmut, Weiterstadt, GERMANY, FEDERAL REPUBLIC OF  
 PI US 2003216385 A1 20031120  
 AI US 2002-276720 A1 20021118 (10)  
 WO 2001-JP4128 20010517  
 DT Utility  
 FS APPLICATION  
 LREP SUGHRUE MION, PLLC, 2100 PENNSYLVANIA AVENUE, N.W., WASHINGTON, DC,  
 20037  
 CLMN Number of Claims: 7  
 ECL Exemplary Claim: 1  
 DRWN No Drawings  
 LN.CNT 2523  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB The invention relates to a triazole derivative with an activity  
 inhibiting glycine transporter and for use as a pharmaceutical drug, and  
 a novel triazole derivative. The inventive triazole derivative has an  
 excellent activity inhibiting glycine transporter and is useful as a  
 therapeutic agent of dementia, schizophrenia, cognitive disorders, or  
 cognitive disorders involved in various diseases such as Alzheimer  
 disease, Parkinson's disease, or Huntington disease or the like, or  
 spasm involved in diseases such as nerve degenerative diseases and  
 cerebrovascular disorders, or the like. Particularly, the pharmaceutical  
 drug is useful for the amelioration of learning disability of dementia  
 and the like.  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 IT 374887-14-6P 374887-16-8P 374887-17-9P  
 (preparation of triazole derivs. as glycine transporter inhibitors)  
 RN 374887-14-6 USPATFULL  
 CN Piperidine, 1-[5-ethyl-4-(2-fluorophenyl)-4H-1,2,4-triazol-3-yl]-4-phenyl-  
 (9CI) (CA INDEX NAME)




RN 374887-16-8 USPATFULL  
 CN Piperidine, 4-[5-ethyl-4-(2-fluorophenyl)-4H-1,2,4-triazol-3-yl]-1-phenyl-  
 (9CI) (CA INDEX NAME)





RN 374887-17-9 USPATFULL

CN Piperazine, 1-[5-ethyl-4-(2-fluorophenyl)-4H-1,2,4-triazol-3-yl]-4-phenyl-  
(9CI) (CA INDEX NAME)



=> b home

FILE 'HOME' ENTERED AT 09:25:57 ON 22 SEP 2005

=>